Q2 2014 Earnings Release 8-K

0000014272-14-000212.txt : 20140724 0000014272-14-000212.hdr.sgml : 20140724 20140724083552 ACCESSION NUMBER: 0000014272-14-000212 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20140724 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20140724 DATE AS OF CHANGE: 20140724 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BRISTOL MYERS SQUIBB CO CENTRAL INDEX KEY: 0000014272 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 220790350 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-01136 FILM NUMBER: 14990175 BUSINESS ADDRESS: STREET 1: 345 PARK AVE CITY: NEW YORK STATE: NY ZIP: 10154 BUSINESS PHONE: 2125464000 MAIL ADDRESS: STREET 1: 345 PARK AVE CITY: NEW YORK STATE: NY ZIP: 10154 FORMER COMPANY: FORMER CONFORMED NAME: BRISTOL MYERS CO DATE OF NAME CHANGE: 19891012 8-K 1 q22014earningsrelease8-k.htm FORM 8-K Q2 2014 Earnings Release 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act Of 1934

Date of Report (Date of earliest event reported): July 24, 2014

BRISTOL-MYERS SQUIBB COMPANY

(Exact Name of Registrant as Specified in its Charter)




Delaware	1-1136	22-0790350
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification Number)

345 Park Avenue

New York, NY 10154

(Address of Principal Executive Office)

Registrant’s telephone number, including area code: (212) 546-4000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):



¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)



¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)



¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))



¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. Results of Operations and Financial Condition.

On July 24, 2014, Bristol-Myers Squibb Company (the “Company”) issued a press release announcing its financial results for the second quarter of 2014. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference. Also furnished and incorporated by reference as Exhibit 99.2 is certain supplemental information posted on the Company’s website at www.bms.com.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.




99.1	Press release of Bristol-Myers Squibb Company dated July 24, 2014.

99.2	Certain supplemental information posted on Bristol-Myers Squibb Company’s website at www.bms.com not included in the press release.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



	BRISTOL-MYERS SQUIBB COMPANY

Dated: July 24, 2014	By:	/s/ Sandra Leung
	Name:	Sandra Leung
	Title:	General Counsel and Corporate Secretary

EXHIBIT INDEX




Exhibit No.	Description

99.1	Press release of Bristol-Myers Squibb Company dated July 24, 2014.

99.2	Certain supplemental information posted on Bristol-Myers Squibb Company’s website at www.bms.com not included in the press release.

EX-99.1 2 q22014ex991.htm PRESS RELEASE OF BRISTOL-MYERS SQUIBB COMPANY DATED JULY 24, 2014 Q2 2014 Ex. 99.1

Exhibit 99.1

Bristol-Myers Squibb Reports Second Quarter 2014 Financial Results


•	Posts Second Quarter GAAP EPS of $0.20 and Non-GAAP EPS of $0.48


•	Achieves Important Regulatory Milestones across Portfolio


◦	Approval for Daklinza+Sunvepra Dual Regimen in Japan


◦	Positive Advisory Opinions for Daklinza and Eliquis in Europe


◦	Plans for Third Quarter Submission of a Biologics License Application in the U.S. for

Opdivo for Previously Treated Advanced Melanoma


•	Announces Strategic Immuno-Oncology Collaboration with Ono Pharmaceutical Co., Ltd.


•	Adjusts 2014 GAAP EPS Guidance Range to $1.50-$1.60 and Confirms Non-GAAP EPS Guidance Range of $1.70-$1.80

NEW YORK (July 24, 2014) - Bristol-Myers Squibb Company (NYSE:BMY) today reported financial results for the second quarter of 2014, which was highlighted by strong global sales for the company’s key brands; the achievement of important regulatory milestones for key brands in Japan, Europe and the U.S.; a new strategic immuno-oncology collaboration agreement with Ono Pharmaceutical Co., Ltd.; and the initiation of several research collaborations that will strengthen the company’s leadership position in immuno-oncology. In addition, the company adjusted 2014 GAAP guidance and confirmed 2014 non-GAAP guidance.

“During the second quarter we delivered strong financial and operating results, invested in key business development opportunities, and achieved important regulatory milestones for products in HCV and immuno-oncology,” said Lamberto Andreotti, chief executive officer, Bristol-Myers Squibb. “These results reflect the promise of our late-stage pipeline, the strong performance of our in-line products and the continued success of our strategy in driving growth for the company.”



	Second Quarter
$ amounts in millions, except per share amounts
	2014		2013		Change
Total Revenues	$	3,889	$	4,048	(4	)%
GAAP Diluted EPS	0.20		0.32		(38	)%
Non-GAAP Diluted EPS	0.48		0.44		9	%

SECOND QUARTER FINANCIAL RESULTS


•	Bristol-Myers Squibb posted second quarter 2014 revenues of $3.9 billion, a decrease of 4% compared to the same period a year ago. Excluding the divested Diabetes Alliance, global revenues increased 7%.


•	U.S. revenues decreased 7% to $1.9 billion in the quarter compared to the same period a year ago. International revenues decreased 1% to $2.0 billion.


•	Gross margin as a percentage of revenues was 74.5% in the quarter compared to 72.6% in the same period a year ago.


•	Marketing, selling and administrative expenses decreased 9% to $951 million in the quarter.


•	Advertising and product promotion spending decreased 14% to $187 million in the quarter.


•	Research and development expenses increased 49% to $1.4 billion in the quarter and included impairment and acquisition-related charges of $458 million.


•	The effective tax rate on earnings before income taxes was 25.4% in the quarter, compared to 0% in the second quarter last year. Income taxes in the second quarter last year reflect a more favorable earnings mix between high and low tax jurisdictions, primarily driven by specified items.


•	The company reported net earnings attributable to Bristol-Myers Squibb of $333 million, or $0.20 per share, in the quarter compared to $536 million, or $0.32 per share, a year ago.


•	The company reported non-GAAP net earnings attributable to Bristol-Myers Squibb of $798 million, or $0.48 per share, in the second quarter, compared to $730 million, or $0.44 per share, for the same period in 2013. An overview of specified items is discussed under the “Use of Non-GAAP Financial Information” section.


•	Cash, cash equivalents and marketable securities were $11.1 billion, with a net cash position of $3.3 billion, as of June 30, 2014.

SECOND QUARTER PRODUCT AND PIPELINE UPDATE

Bristol-Myers Squibb’s global sales in the second quarter included Eliquis, which grew by $159 million, Yervoy, which grew 38%, Sprycel, which grew 18%, and Orencia, which grew 14%.

Daklinza+Sunvepra

•

In July, the company announced that the Japanese Ministry of Health, Labor and Welfare has approved Daklinza (daclatasvir), the company’s potent, pan-genotypic NS5A replication complex inhibitor (in vitro), and Sunvepra (asunaprevir), the company’s NS3/4A protease inhibitor. The approvals are Japan’s first for an all-oral, interferon- and ribavirin-free treatment regimen for patients with genotype 1 chronic hepatitis C virus infection, particularly those with compensated cirrhosis. The Daklinza+Sunvepra Dual Regimen provides a new treatment alternative that can lead to cure for many patients in Japan who currently have no treatment options. Daklinza and Sunvepra are expected to be commercially available in Japan in early September.

•

In June, the company announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending that Daklinza be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus infection in adults. This is the first positive opinion given by the CHMP for an NS5A inhibitor. It will now be reviewed by the European Commission (EC), which has the authority to approve medicines for all European Union (EU) member states plus Iceland and Norway.

•

In April, the company announced the submission of New Drug Applications (NDAs) for Daklinza and Sunvepra to the U.S. Food and Drug Administration (FDA). The data submitted in the NDAs support use of the Daklinza+Sunvepra Dual Regimen in patients with genotype 1b hepatitis C. The Daklinza NDA also seeks approval for use of this compound in combination with other agents for multiple genotypes. The FDA accepted the submissions for filing and assigned both submissions priority review with a user fee goal date of November 30, 2014.

Opdivo

•

In July, the company announced that, following discussions with the FDA, the company is planning a third quarter submission of a Biologics License Application (BLA) for Opdivo (nivolumab) for previously treated advanced melanoma. This will mark the second tumor type for which Bristol-Myers Squibb has a regulatory submission under way for Opdivo in the U.S. In April, the company initiated a rolling BLA submission for Opdivo in third-line squamous cell non-small cell lung cancer (NSCLC). The company expects to complete the first submission by the end of the year.

•

In June, the company announced that a randomized, blinded comparative Phase III study evaluating Opdivo versus dacarbazine in patients with previously untreated BRAF wild-type advanced melanoma (CheckMate -066) was stopped early because an analysis conducted by the independent Data Monitoring Committee showed evidence of superior overall survival in patients receiving Opdivo compared to the control arm.

•

Also in June, at the American Society of Clinical Oncology (ASCO) meeting in Chicago, the company announced results from several clinical trials for Opdivo, both as monotherapy and in combination with Yervoy, in advanced cancers of the lungs, skin and kidneys. Bristol-Myers Squibb is at the forefront of research and discovery in the field of immuno-oncology and these data add to the growing body of research from its leading immuno-oncology pipeline, further supporting the scientific rationale for the potential of these checkpoint inhibitors as single agents or as part of a combination regimen.


•	In May, the FDA granted Opdivo Breakthrough Therapy Designation for the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab. The designation is based on data from a cohort of patients with Hodgkin lymphoma in the company’s ongoing Phase Ib study of relapsed and refractory hematological malignancies.

Eliquis


•	In July, the company and its partner, Pfizer, announced that the first patient has enrolled in a Phase IV clinical trial assessing the effectiveness and safety of Eliquis in patients with nonvalvular atrial fibrillation undergoing cardioversion.

•

In June, the company and its partner, Pfizer, announced that CHMP has adopted a positive opinion recommending that Eliquis be granted marketing authorization for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and the prevention of recurrent DVT and PE, in adults. The CHMP’s positive opinion will now be reviewed by the EC, which has the authority to approve medicines for all EU member states plus Iceland and Norway.

Elotuzumab

•

In May, the company and its partner, AbbVie, announced that the FDA has granted elotuzumab, an investigational humanized monoclonal antibody, Breakthrough Therapy Designation for use in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in patients who have received one or more prior therapies. The designation is based on findings from a randomized Phase II, open-label study that evaluated two dose levels of elotuzumab in combination with lenalidomide and low-dose dexamethasone in previously-treated patients, including the 10 mg/kg dose that is being studied in Phase III trials.

Yervoy

•

In June, at the ASCO meeting in Chicago, the company announced results from a Phase III randomized, double-blind study demonstrating that Yervoy 10 mg/kg (n=475) significantly improved recurrence-free survival (RFS, the length of time before recurrence or death) vs. placebo (n=476) for patients with Stage 3 melanoma who are at high risk of recurrence following complete surgical resection, an adjuvant setting. A 25% reduction in the risk of recurrence or death was observed. At three years, an estimated 46.5% of patients treated with Yervoy were free of disease recurrence compared to an estimated 34.8% of patients on placebo. The median RFS was 26.1 months for Yervoy vs. 17.1 months for placebo, with a median follow-up of 2.7 years.

Orencia

•

In June, at the European League Against Rheumatism meeting in Paris, the company presented data from the Phase IIIb AVERT trial showing that treatment with Orencia, a T-cell co-stimulation modulator, in combination with methotrexate (MTX) achieved significantly higher rates of DAS-defined (DAS28 CRP <2.6) remission at 12 months than treatment with standard of care agent MTX (60.9% vs. 45.2%, respectively), in biologic and MTX-naïve patients with early active rheumatoid arthritis (RA). A small but statistically significantly higher number of patients treated with Orencia plus MTX, versus MTX alone, for 12 months maintained remission 6 months after all RA treatment, including Orencia, MTX or steroids, was withdrawn.

Baraclude


•	In June, the U.S. Court of Appeals for the Federal Circuit denied the company’s appeal of a February 2013 ruling by the U.S. District Court for the District of Delaware that found invalid the patent covering Baraclude (U.S. patent 5,206,244). In July, the company filed a petition for an en banc rehearing of the case by the full U.S. Court of Appeals.

SECOND QUARTER BUSINESS DEVELOPMENT UPDATE

•

In July, the company and Ono Pharmaceutical Co., Ltd., signed a collaboration agreement to jointly develop and commercialize Opdivo, Yervoyand three immunotherapy agents in early clinical development as single agents and combination regimens in Japan, South Korea and Taiwan. Also in July, Ono announced that Opdivo received manufacturing and marketing approval in Japan for the treatment of unresectable melanoma. Opdivo is the first PD-1 immune checkpoint inhibitor to receive regulatory approval anywhere in the world.


•	In June, the company and Syngene International announced a five-year extension of their drug discovery and development collaboration at the Biocon Bristol-Myers Squibb Research Center in Bangalore, India.


•	In May, the company announced a clinical trial collaboration with Incyte Corporation to evaluate the safety, tolerability and preliminary efficacy of a combination regimen of Opdivo and INCB24360, Incyte’s oral indoleamine dioxygenase-1 inhibitor, in a Phase I/II study.

•

In May, the company also announced a clinical trial collaboration with Celldex Therapeutics to evaluate the safety, tolerability and preliminary efficacy of Opdivo and varlilumab, Celldex’s CD27 targeting investigational antibody, in a Phase I/II study. Multiple tumor types will be explored in the study, which could potentially include NSCLC, metastatic melanoma, ovarian, colorectal and squamous cell head and neck cancers.


•	In May, the company and CytomX Therapeutics announced a worldwide research collaboration and license agreement to discover, develop and commercialize novel therapies against multiple immuno-oncology targets using CytomX’s proprietary Probody^™ Platform.

SECOND QUARTER RESEARCH & DEVELOPMENT UPDATE

•

In June, the company announced a collaboration with Duke University, through its Duke Clinical Research Institute (DCRI), that will focus on clinical trial transparency. The company will expand access to a broader set of clinical trial information from in-scope company-sponsored studies and enable an independent scientific review through DCRI of requests from researchers that meet pre-specified requirements.

2014 FINANCIAL GUIDANCE

Bristol-Myers Squibb is adjusting its 2014 GAAP EPS guidance range from $1.70-$1.80 to $1.50-$1.60 as a result of impairment and expected additional restructuring charges. The company is also confirming its non-GAAP EPS guidance range of $1.70-$1.80. Both GAAP and non-GAAP guidance assume current exchange rates and that we retain exclusivity on Baraclude sales in the U.S. at least through the end of 2014. Key 2014 non-GAAP line-item guidance assumptions remain unchanged.

The financial guidance for 2014 does not include the impact of any potential strategic acquisition and divestitures, or any specified items that have not yet been identified and quantified. The non-GAAP 2014 guidance also excludes specified items as discussed under “Use of Non-GAAP Financial Information.” Details reconciling adjusted non-GAAP amounts with the amounts reflecting specified items are provided in supplemental materials available on the company’s website.

Use of Non-GAAP Financial Information

This press release contains non-GAAP financial measures, including non-GAAP earnings and related earnings per share information. These measures are adjusted to exclude certain costs, expenses, significant gains and losses and other specified items. Among the items in GAAP measures but excluded for purposes of determining adjusted earnings and other adjusted measures are: restructuring and other exit costs; accelerated depreciation charges; IPRD and asset impairments; charges and recoveries relating to significant legal proceedings; upfront, milestone and other payments for in-licensing of products that have not achieved regulatory approval which are immediately expensed; net amortization of acquired intangible assets and deferred income related to Amylin; pension settlement charges; and significant tax events. This information is intended to enhance an investor’s overall understanding of the company’s past financial performance and prospects for the future. Non-GAAP financial measures provide the company and its investors with an indication of the company’s baseline performance before items that are considered by the company not to be reflective of the company’s ongoing results. The company uses non-GAAP gross profit, non-GAAP marketing, selling and administrative expense, non-GAAP research and development expense, and non-GAAP other income and expense measures to set internal budgets, manage costs, allocate resources, and plan and forecast future periods. Non-GAAP effective tax rate measures are primarily used to plan and forecast future periods.

Non-GAAP earnings and earnings per share measures are primary indicators the company uses as a basis for evaluating company performance, setting incentive compensation targets, and planning and forecasting of future periods. This information is not intended to be considered in isolation or as a substitute for financial measures prepared in accordance with GAAP.

Statement on Cautionary Factors

This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans and projections regarding the company’s financial position, results of operations, market position, product development and business strategy. These statements may be identified by the fact that they use words such as "anticipate", "estimates", "should", "expect", "guidance", "project", "intend", "plan", "believe" and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. These factors include, among other things, effects of the continuing implementation of governmental laws and regulations related to Medicare, Medicaid, Medicaid managed care organizations and entities under the Public Health Service 340B program, pharmaceutical rebates and reimbursement, market factors, competitive product development and approvals, pricing controls and pressures (including changes in rules and practices of managed care groups and institutional and governmental purchasers), economic conditions such as interest rate and currency exchange rate fluctuations, judicial decisions, claims and concerns that may arise regarding the safety and efficacy of in-line products and product candidates, changes to wholesaler inventory levels, variability in data provided by third parties, changes in, and interpretation of, governmental regulations and legislation affecting domestic or foreign operations, including tax obligations, changes to business or tax planning strategies which take into account assumptions about the continued extension of the R&D tax credit, difficulties and delays in product development, manufacturing or sales including any potential future recalls, patent positions and the ultimate outcome of any litigation matter. These factors also include the company’s ability to execute successfully its strategic plans, including its business strategy, the expiration of patents or data protection on certain products, including assumptions about the company’s ability to retain patent exclusivity of certain products, and the impact and result of governmental investigations. There can be no guarantees with respect to pipeline products that future clinical studies will support the data described in this release, that the compounds will receive necessary regulatory approvals, or that they will prove to be commercially successful; nor are there guarantees that regulatory approvals will be sought, or sought within currently expected timeframes, or that contractual milestones will be achieved. For further details and a discussion of these and other risks and uncertainties, see the company's periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Company and Conference Call Information

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit http://www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.

There will be a conference call on July 24, 2014, at 10:30 a.m. EDT during which company executives will review financial information and address inquiries from investors and analysts. Investors and the general public are invited to listen to a live webcast of the call at http://investor.bms.com or by dialing 913-312-6681, confirmation code: 3903092. Materials related to the call will be available at the same website prior to the conference call.

For more information, contact: Laura Hortas, 609-252-4587, laura.hortas@bms.com, Communications; John Elicker, 609-252-4611, john.elicker@bms.com, Ranya Dajani, 609-252-5330, ranya.dajani@bms.com, or Ryan Asay, 609-252-5020, ryan.asay@bms.com, Investor Relations.

BRISTOL-MYERS SQUIBB COMPANY

SELECTED PRODUCTS

FOR THE THREE MONTHS ENDED JUNE 30, 2014 AND 2013

(Unaudited, dollars in millions)



	Worldwide Revenues						U.S. Revenues
	2014		2013		% Change		2014		2013		% Change
Three Months Ended June 30,
Key Products
Virology
Baraclude	$	369	$	371	(1	)%	$	84	$	73	15	%
Reyataz	362		431		(16	)%	168		200		(16	)%
Sustiva Franchise	361		411		(12	)%	266		275		(3	)%
Oncology
Erbitux^(a)	186		171		9	%	178		168		6	%
Sprycel	368		312		18	%	163		135		21	%
Yervoy	321		233		38	%	173		140		24	%
Neuroscience
Abilify^(b)	555		563		(1	)%	417		378		10	%
Immunoscience
Orencia	402		352		14	%	254		238		7	%
Cardiovascular
Eliquis	171		12		**		94		5		**

Diabetes Alliance	27		438		(94	)%	—		320		(100	)%

Mature Products and All Other	767		754		2	%	104		113		(8	)%

Total	3,889		4,048		(4	)%	1,901		2,045		(7	)%

Total Excluding Diabetes Alliance	3,862		3,610		7	%	1,901		1,725		10	%



**	In excess of 100%

(a)	Erbitux is a trademark of ImClone LLC. ImClone LLC is a wholly-owned subsidiary of Eli Lilly and Company.
(b)	Abilify is a trademark of Otsuka Pharmaceutical Co., Ltd.

BRISTOL-MYERS SQUIBB COMPANY

SELECTED PRODUCTS

FOR THE SIX MONTHS ENDED JUNE 30, 2014 AND 2013

(Unaudited, dollars in millions)



	Worldwide Revenues						U.S. Revenues
	2014		2013		% Change		2014		2013		% Change
Six Months Ended June 30,
Key Products
Virology
Baraclude	$	775	$	737	5	%	$	154	$	141	9	%
Reyataz	706		792		(11	)%	344		393		(12	)%
Sustiva Franchise	680		798		(15	)%	494		526		(6	)%
Oncology
Erbitux	355		333		7	%	336		326		3	%
Sprycel	710		599		19	%	308		250		23	%
Yervoy	592		462		28	%	319		299		7	%
Neuroscience
Abilify	1,095		1,085		1	%	742		706		5	%
Immunoscience
Orencia	765		672		14	%	483		452		7	%
Cardiovascular
Eliquis	277		34		**		155		22		**

Diabetes Alliance	206		796		(74	)%	114		612		(81	)%

Mature Products and All Other	1,539		1,571		(2	)%	217		289		(25	)%

Total	7,700		7,879		(2	)%	3,666		4,016		(9	)%

Total Excluding Diabetes Alliance	7,494		7,083		6	%	3,552		3,404		4	%



**	In excess of 100%

BRISTOL-MYERS SQUIBB COMPANY

CONSOLIDATED STATEMENTS OF EARNINGS

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2014 AND 2013

(Unaudited, dollars and shares in millions except per share data)



	Three Months Ended June 30,						Six Months Ended June 30,
	2014			2013			2014			2013
Net product sales	$	2,770		$	3,024		$	5,577		$	5,981
Alliance and other revenues	1,119			1,024			2,123			1,898
Total Revenues	3,889			4,048			7,700			7,879

Cost of products sold	991			1,108			1,959			2,171
Marketing, selling and administrative	951			1,042			1,908			2,036
Advertising and product promotion	187			218			350			407
Research and development	1,416			951			2,362			1,881
Other (income)/expense	(104		)	199			(312		)	180
Total Expenses	3,441			3,518			6,267			6,675

Earnings Before Income Taxes	448			530			1,433			1,204
Provision for Income Taxes	114			—			163			51

Net Earnings	334			530			1,270			1,153
Net Earnings/(Loss) Attributable to Noncontrolling Interest	1			(6		)	—			8
Net Earnings Attributable to BMS	$	333		$	536		$	1,270		$	1,145

Earnings per Common Share
Basic	$	0.20		$	0.33		$	0.77		$	0.70
Diluted	$	0.20		$	0.32		$	0.76		$	0.69

Average Common Shares Outstanding:
Basic	1,657			1,644			1,655			1,641
Diluted	1,669			1,660			1,668			1,658

Other (Income)/Expense

Interest expense	$	46		$	50		$	100		$	100
Investment income	(28		)	(28		)	(51		)	(53		)
Provision for restructuring	16			173			37			206
Litigation charges/(recoveries)	(20		)	(22		)	9			(22		)
Equity in net income of affiliates	(33		)	(50		)	(69		)	(86		)
Gain on sale of product lines, businesses and assets	7			—			(252		)	(1		)
Other alliance and licensing income	(144		)	(32		)	(252		)	(89		)
Pension curtailments, settlements and special termination benefits	45			101			109			101
Other	7			7			57			24
Other (income)/expense	$	(104	)	$	199		$	(312	)	$	180

BRISTOL-MYERS SQUIBB COMPANY

SPECIFIED ITEMS

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2014 AND 2013

(Unaudited, dollars in millions)



	Three Months Ended June 30,						Six Months Ended June 30,
	2014			2013			2014			2013
Accelerated depreciation, asset impairment and other shutdown costs	$	39		$	—		$	84		$	—
Amortization of acquired Amylin intangible assets	—			137			—			275
Amortization of Amylin alliance proceeds	—			(67		)	—			(134		)
Amortization of Amylin inventory adjustment	—			—			—			14
Cost of products sold	39			70			84			155

Marketing, selling and administrative*	3			1			6			2

Upfront, milestone and other payments	148			—			163			—
IPRD impairments	310			—			343			—
Research and development	458			—			506			—

Provision for restructuring	16			173			37			206
Gain on sale of product lines, businesses and assets	12			—			(247		)	—
Pension curtailments, settlements and special termination benefits	45			99			109			99
Acquisition and alliance related items	17			(10		)	33			(10		)
Litigation charges/(recoveries)	(23		)	(23		)	2			(23		)
Loss on debt redemption	—			—			45			—
Upfront, milestone and other licensing receipts	—			—			—			(14		)
Other (income)/expense	67			239			(21		)	258

Increase to pretax income	567			310			575			415
Income tax on items above	(102		)	(116		)	(281		)	(151		)
Increase to net earnings	$	465		$	194		$	294		$	264

* Specified items in marketing, selling and administrative are process standardization implementation costs.

BRISTOL-MYERS SQUIBB COMPANY

RECONCILIATION OF CERTAIN NON-GAAP LINE ITEMS TO CERTAIN GAAP LINE ITEMS

FOR THE THREE MONTHS ENDED JUNE 30, 2014 AND 2013

(Unaudited, dollars in millions)



Three months ended June 30, 2014	GAAP			Specified Items*			Non GAAP
Gross Profit	$	2,898		$	39		$	2,937
Marketing, selling and administrative	951			(3		)	948
Research and development	1,416			(458		)	958
Other (income)/expense	(104		)	(67		)	(171		)
Effective Tax Rate	25.4		%	(4.1		)%	21.3		%

Three months ended June 30, 2013	GAAP			Specified Items*			Non GAAP
Gross Profit	$	2,940		$	70		$	3,010
Marketing, selling and administrative	1,042			(1		)	1,041
Research and development	951			—			951
Other (income)/expense	199			(239		)	(40		)
Effective Tax Rate	—			13.8		%	13.8		%



*	Refer to the Specified Items schedule for further details. Effective tax rate on the Specified Items represents the difference between the GAAP and Non-GAAP effective tax rate.

BRISTOL-MYERS SQUIBB COMPANY

RECONCILIATION OF CERTAIN NON-GAAP LINE ITEMS TO CERTAIN GAAP LINE ITEMS

FOR THE SIX MONTHS ENDED JUNE 30, 2014 AND 2013

(Unaudited, dollars in millions)



Six Months Ended June 30, 2014	GAAP			Specified Items*			Non GAAP
Gross Profit	$	5,741		$	84		$	5,825
Marketing, selling and administrative	1,908			(6		)	1,902
Research and development	2,362			(506		)	1,856
Other (income)/expense	(312		)	21			(291		)
Effective Tax Rate	11.4		%	10.7		%	22.1		%

Six Months Ended June 30, 2013	GAAP			Specified Items*			Non GAAP
Gross Profit	$	5,708		$	155		$	5,863
Marketing, selling and administrative	2,036			(2		)	2,034
Research and development	1,881			—			1,881
Other (income)/expense	180			(258		)	(78		)
Effective Tax Rate	4.2		%	8.3		%	12.5		%



*	Refer to the Specified Items schedule for further details. Effective tax rate on the Specified Items represents the difference between the GAAP and Non-GAAP effective tax rate.

BRISTOL-MYERS SQUIBB COMPANY

RECONCILIATION OF NON-GAAP EPS TO GAAP EPS

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2014 AND 2013

(Unaudited, dollars and shares in millions except per share data)



	Three Months Ended June 30,				Six Months Ended June 30,
	2014		2013		2014		2013
Net Earnings Attributable to BMS used for Diluted EPS Calculation - GAAP	$	333	$	536	$	1,270	$	1,145
Less Specified Items*	465		194		294		264
Net Earnings used for Diluted EPS Calculation – Non-GAAP	$	798	$	730	$	1,564	$	1,409

Average Common Shares Outstanding – Diluted	1,669		1,660		1,668		1,658

Diluted Earnings Per Share — GAAP	$	0.20	$	0.32	$	0.76	$	0.69
Diluted EPS Attributable to Specified Items	0.28		0.12		0.18		0.16
Diluted Earnings Per Share — Non-GAAP	$	0.48	$	0.44	$	0.94	$	0.85



*	Refer to the Specified Items schedule for further details.

BRISTOL-MYERS SQUIBB COMPANY

NET CASH/(DEBT) CALCULATION

AS OF JUNE 30, 2014 AND MARCH 31, 2014

(Unaudited, dollars in millions)



	June 30, 2014			March 31, 2014
Cash and cash equivalents	$	4,282		$	5,225
Marketable securities - current	2,893			1,834
Marketable securities - long term	3,876			3,558
Cash, cash equivalents and marketable securities	11,051			10,617
Short-term borrowings and current portion of long-term debt	(365		)	(281		)
Long-term debt	(7,372		)	(7,367		)
Net cash position	$	3,314		$	2,969

EX-99.2 3 q22014ex992.htm CERTAIN SUPPLEMENTAL INFORMATION Q2 2014 Ex. 99.2

Exhibit 99.2

BRISTOL-MYERS SQUIBB COMPANY

QUARTERLY TREND ANALYSIS OF REVENUES

(Unaudited, dollars in millions)



Revenues	2013																					2014													% Change		FX Impact
	1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year			1st Qtr			2nd Qtr			6 Months			3rd Qtr	9 Months	4th Qtr	Year	Qtr vs. Qtr	YTD vs. YTD	Qtr vs. Qtr	YTD vs. YTD
Total	$	3,831		$	4,048		$	7,879		$	4,065		$	11,944		$	4,441		$	16,385		$	3,811		$	3,889		$	7,700						(4)%	(2)%	—	—
US and Puerto Rico	1,971			2,045			4,016			2,037			6,053			2,265			8,318			1,765			1,901			3,666							(7)%	(9)%	—	—
Europe	946			950			1,896			985			2,881			1,049			3,930			948			908			1,856							(4)%	(2)%	4%	3%
Rest of the World	765			835			1,600			805			2,405			890			3,295			830			811			1,641							(3)%	3%	(4)%	(5)%
Other	149			218			367			238			605			237			842			268			269			537							23%	46%	—	—

% of Revenues	2013																					2014
	1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year			1st Qtr			2nd Qtr			6 Months			3rd Qtr	9 Months	4th Qtr	Year
Total	100.0		%	100.0		%	100.0		%	100.0		%	100.0		%	100.0		%	100.0		%	100.0		%	100.0		%	100.0		%
US and Puerto Rico	51.4		%	50.5		%	51.0		%	50.1		%	50.7		%	51.0		%	50.8		%	46.3		%	48.9		%	47.6		%
Europe	24.7		%	23.5		%	24.1		%	24.2		%	24.1		%	23.6		%	24.0		%	24.9		%	23.3		%	24.1		%
Rest of the World	20.0		%	20.6		%	20.3		%	19.8		%	20.1		%	20.0		%	20.1		%	21.8		%	20.9		%	21.3		%
Other	3.9		%	5.4		%	4.6		%	5.9		%	5.1		%	5.4		%	5.1		%	7.0		%	6.9		%	7.0		%

BRISTOL-MYERS SQUIBB COMPANY

REVENUES AND COMPOSITION OF CHANGE IN REVENUES

FOR THE PERIOD ENDED JUNE 30, 2014

(Unaudited, dollars in millions)



QUARTER-TO-DATE	Revenues				Analysis of % Change
	2014		2013		Total Change	Volume	Price	Foreign Exchange
US and Puerto Rico	$	1,901	$	2,045	(7)%	(12)%	5%	—
Europe	908		950		(4)%	(1)%	(7)%	4%
Rest of the World	811		835		(3)%	3%	(2)%	(4)%
Other	269		218		23%	N/A	N/A	—
Total	$	3,889	$	4,048	(4)%	(5)%	1%	—

YEAR-TO-DATE	Revenues				Analysis of % Change
	2014		2013		Total Change	Volume	Price	Foreign Exchange
US and Puerto Rico	$	3,666	$	4,016	(9)%	(12)%	3%	—
Europe	1,856		1,896		(2)%	2%	(7)%	3%
Rest of the World	1,641		1,600		3%	10%	(2)%	(5)%
Other	537		367		46%	N/A	N/A	—
Total	$	7,700	$	7,879	(2)%	(2)%	—	—

BRISTOL-MYERS SQUIBB COMPANY

EARNINGS FROM OPERATIONS

(Unaudited, dollars and shares in millions except per share data)



	2013																					2014													% Change
	1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year			1st Qtr			2nd Qtr			6 Months			3rd Qtr	9 Months	4th Qtr	Year	Qtr vs. Qtr	YTD vs. YTD
Net product sales	$	2,957		$	3,024		$	5,981		$	3,025		$	9,006		$	3,298		$	12,304		$	2,807		$	2,770		$	5,577						(8)%	(7)%
Alliance and other revenues	874			1,024			1,898			1,040			2,938			1,143			4,081			1,004			1,119			2,123							9%	12%
Total Revenues	$	3,831		$	4,048		$	7,879		$	4,065		$	11,944		$	4,441		$	16,385		$	3,811		$	3,889		$	7,700						(4)%	(2)%

Cost of products sold	1,063			1,108			2,171			1,175			3,346			1,273			4,619			968			991			1,959							(11)%	(10)%
Marketing, selling and administrative	994			1,042			2,036			980			3,016			1,068			4,084			957			951			1,908							(9)%	(6)%
Advertising and product promotion	189			218			407			194			601			254			855			163			187			350							(14)%	(14)%
Research and development	930			951			1,881			893			2,774			957			3,731			946			1,416			2,362							49%	26%
Other (income)/expense	(19		)	199			180			5			185			20			205			(208		)	(104		)	(312		)					**	**
Total Expenses	3,157			3,518			6,675			3,247			9,922			3,572			13,494			2,826			3,441			6,267							(2)%	(6)%

Earnings Before Income Taxes	$	674		$	530		$	1,204		$	818		$	2,022		$	869		$	2,891		$	985		$	448		$	1,433						(15)%	19%
Provision for Income Taxes	51			—			51			126			177			134			311			49			114			163							—	**
Net Earnings	$	623		$	530		$	1,153		$	692		$	1,845		$	735		$	2,580		$	936		$	334		$	1,270						(37)%	10%
Net Earnings/(Loss) Attributable to Noncontrolling Interest	14			(6		)	8			—			8			9			17			(1		)	1			—							**	(100)%
Net Earnings Attributable to BMS	$	609		$	536		$	1,145		$	692		$	1,837		$	726		$	2,563		$	937		$	333		$	1,270						(38)%	11%

Diluted Earnings per Common Share*	$	0.37		$	0.32		$	0.69		$	0.42		$	1.11		$	0.44		$	1.54		$	0.56		$	0.20		$	0.76						(38)%	10%
Average Common Shares Outstanding - Diluted	1,655			1,660			1,658			1,662			1,659			1,666			1,662			1,666			1,669			1,668							1%	1%
Dividends declared per common share	$	0.35		$	0.35		$	0.70		$	0.35		$	1.05		$	0.36		$	1.41		$	0.36		$	0.36		$	0.72						3%	3%


	2013																					2014
% of Total Revenues	1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year			1st Qtr			2nd Qtr			6 Months			3rd Qtr	9 Months	4th Qtr	Year
Gross Margin	72.3		%	72.6		%	72.4		%	71.1		%	72.0		%	71.3		%	71.8		%	74.6		%	74.5		%	74.6		%

Other Ratios
Effective tax rate	7.6		%	—			4.2		%	15.4		%	8.8		%	15.4		%	10.8		%	5.0		%	25.4		%	11.4		%

Other (Income)/Expense	2013																					2014													% Change
	1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year			1st Qtr			2nd Qtr			6 Months			3rd Qtr	9 Months	4th Qtr	Year	Qtr vs. Qtr	YTD vs. YTD
Interest expense	$	50		$	50		$	100		$	46		$	146		$	53		$	199		$	54		$	46		$	100						(8)%	—
Investment income	(25		)	(28		)	(53		)	(23		)	(76		)	(28		)	(104		)	(23		)	(28		)	(51		)					—	4%
Provision for restructuring	33			173			206			6			212			14			226			21			16			37							(91)%	(82)%
Litigation charges/(recoveries)	—			(22		)	(22		)	17			(5		)	25			20			29			(20		)	9							9%	**
Equity in net income of affiliates	(36		)	(50		)	(86		)	(42		)	(128		)	(38		)	(166		)	(36		)	(33		)	(69		)					34%	20%
Gain on sale of product lines, businesses and assets	(1		)	—			(1		)	—			(1		)	(1		)	(2		)	(259		)	7			(252		)					N/A	**
Other alliance and licensing income	(57		)	(32		)	(89		)	(31		)	(120		)	(28		)	(148		)	(108		)	(144		)	(252		)					**	**
Pension curtailments, settlements and special termination benefits	—			101			101			37			138			27			165			64			45			109							(55)%	8%
Other	17			7			24			(5		)	19			(4		)	15			50			7			57							—	**
	$	(19	)	$	199		$	180		$	5		$	185		$	20		$	205		$	(208	)	$	(104	)	$	(312	)					**	**

* Quarterly amounts may not add to the year-to-date totals due to rounding of individual calculations.

** In excess of 100%

BRISTOL-MYERS SQUIBB COMPANY

RECONCILIATION OF GAAP AND NON-GAAP GROWTH DOLLARS AND PERCENTAGES EXCLUDING FOREIGN EXCHANGE IMPACT

FOR THE PERIOD ENDED JUNE 30, 2014

(Unaudited, dollars in millions)

QUARTER-TO-DATE



	2014			2013			Growth $		Growth %	Favorable / (Unfavorable) FX Impact $ *			2014 Excluding FX		Favorable / (Unfavorable) FX Impact % *	Growth % Excluding FX
Revenues	$	3,889		$	4,048		(159	)	(4)%	$	10		$	3,879	—	(4)%
Gross profit	2,898			2,940			(42	)	(1)%	N/A			N/A		N/A	N/A
Gross profit excluding specified items^(a)	2,937			3,010			(73	)	(2)%	N/A			N/A		N/A	N/A
Gross profit excluding specified items as a % of revenues	75.5		%	74.4		%

Marketing, selling and administrative	951			1,042			(91	)	(9)%	2			953		—	(9)%
Marketing, selling and administrative excluding specified items^(a)	948			1,041			(93	)	(9)%	2			950		—	(9)%

Advertising and product promotion	187			218			(31	)	(14)%	—			187		—	(14)%

SG&A excluding specified items as a % of revenues	29.2		%	31.1		%

Research and development	1,416			951			465		49%	(4		)	1,412		(1)%	48%
Research and development excluding specified items^(a)	958			951			7		1%	(4		)	954		(1)%	—

Research and development excluding specified items as a % of revenues	24.6		%	23.5		%

YEAR-TO-DATE
	2014			2013			Growth $		Growth %	Favorable / (Unfavorable) FX Impact $ *			2014 Excluding FX		Favorable / (Unfavorable) FX Impact % *	Growth % Excluding FX
Revenues	$	7,700		$	7,879		(179	)	(2)%	$	(14	)	$	7,714	—	(2)%
Gross profit	5,741			5,708			33		1%	N/A			N/A		N/A	N/A
Gross profit excluding specified items^(a)	5,825			5,863			(38	)	(1)%	N/A			N/A		N/A	N/A
Gross profit excluding specified items as a % of revenues	75.6		%	74.4		%

Marketing, selling and administrative	1,908			2,036			(128	)	(6)%	11			1,919		—	(6)%
Marketing, selling and administrative excluding specified items^(a)	1,902			2,034			(132	)	(6)%	11			1,913		—	(6)%

Advertising and product promotion	350			407			(57	)	(14)%	2			352		—	(14)%

SG&A excluding specified items as a % of revenues	29.2		%	31.0		%

Research and development	2,362			1,881			481		26%	(2		)	2,360		(1)%	25%
Research and development excluding specified items^(a)	1,856			1,881			(25	)	(1)%	(2		)	1,854		—	(1)%

Research and development excluding specified items as a % of revenues	24.1		%	23.9		%



(a) Refer to the Specified Items schedule for further details.
* Foreign exchange (FX) impact determined by the change in a line item's current and prior period results at a common exchange rate and comparing this change to the actual reported change from the same period. This difference is determined to be the FX impact.

BRISTOL-MYERS SQUIBB COMPANY

WORLDWIDE REVENUES FROM OPERATIONS BY PRODUCT

QUARTERLY REVENUES TREND ANALYSIS AND RECONCILIATION OF GAAP AND NON-GAAP GROWTH DOLLARS AND PERCENTAGES EXCLUDING FOREIGN EXCHANGE IMPACT

(Unaudited, dollars in millions)



	2013														2014										Growth $						% Change		EX-FX						FX Impact
	1st Qtr		2nd Qtr		6 Months		3rd Qtr		9 Months		4th Qtr		Year		1st Qtr		2nd Qtr		6 Months		3rd Qtr	9 Months	4th Qtr	Year	Qtr vs. Qtr			YTD vs. YTD			Qtr vs. Qtr	YTD vs. YTD	QTD EX-FX $		YTD EX-FX $		Qtr vs. Qtr %	YTD vs. YTD %	Qtr vs. Qtr	YTD vs. YTD
TOTAL	$	3,831	$	4,048	$	7,879	$	4,065	$	11,944	$	4,441	$	16,385	$	3,811	$	3,889	$	7,700					$	(159	)	$	(179	)	(4)%	(2)%	$	3,879	$	7,714	(4)%	(2)%	—	—
Virology ^(a)
Baraclude	366		371		737		378		1,115		412		1,527		406		369		775						(2		)	38			(1)%	5%	367		779		(1)%	6%	1%	(1)%
Reyataz	361		431		792		375		1,167		384		1,551		344		362		706						(69		)	(86		)	(16)%	(11)%	365		713		(15)%	(10)%	(1)%	(1)%
Sustiva Franchise ^(b)	387		411		798		389		1,187		427		1,614		319		361		680						(50		)	(118		)	(12)%	(15)%	356		673		(13)%	(16)%	1%	1%
Oncology ^(a)
Erbitux	162		171		333		183		516		180		696		169		186		355						15			22			9%	7%	187		356		9%	7%	N/A	N/A
Sprycel	287		312		599		316		915		365		1,280		342		368		710						56			111			18%	19%	369		719		18%	20%	—	(1)%
Yervoy	229		233		462		238		700		260		960		271		321		592						88			130			38%	28%	318		588		36%	27%	1%	1%
Neuroscience^(a)
Abilify^(c)	522		563		1,085		569		1,654		635		2,289		540		555		1,095						(8		)	10			(1)%	1%	551		1,089		(2)%	—	1%	1%
Immunoscience^(a)
Orencia^(d)	320		352		672		375		1,047		397		1,444		363		402		765						50			93			14%	14%	405		774		15%	15%	(1)%	(1)%
Cardiovascular^(a)
Eliquis	22		12		34		41		75		71		146		106		171		277						159			243			**	**	170		278		**	**	N/A	N/A

Diabetes Alliance ^(e)	358		438		796		432		1,228		455		1,683		179		27		206						(411		)	(590		)	(94)%	(74)%	27		206		(94)%	(74)%	—	—

Mature Products and All Other ^(f)	817		754		1,571		769		2,340		855		3,195		772		767		1,539						13			(32		)	2%	(2)%	764		1,539		1%	(2)%	1%	—

Total Excluding Diabetes Alliance	3,473		3,610		7,083		3,633		10,716		3,986		14,702		3,632		3,862		7,494						252			411			7%	6%	3,852		7,508		7%	6%	—	—



**	In excess of 100%
(a)	Key products listed do not represent all products in the respective therapeutic areas.
(b)	The Sustiva Franchise includes sales of Sustiva and revenue from sales of bulk efavirenz included in the combination therapy, Atripla. Includes alliance and other revenue of $313M and $346M for the three months ended June 30, 2014 and 2013, respectively, and $585M and $670M for the six months ended June 30, 2014 and 2013, respectively.
(c)	Includes revenue from the co-promotional agreement with Otsuka Pharmaceutical Co., Ltd. Includes alliance and other revenue of $499M and $454M for three months ended June 30, 2014 and 2013, respectively, and $940M and $849M for the six months ended June 30, 2014 and 2013, respectively.
(d)	Includes Orencia SubQ revenues of $160M and $100M for three months ended June 30, 2014 and 2013, respectively, and $296M and $184M for the six months ended June 30, 2014 and 2013, respectively.
(e)	The six months ended June 30, 2014 includes pre-divestiture revenues of Bydureon, Byetta, Farxiga/Forxiga/Xigduo, Onglyza/Kombiglyze, Symlin and Myalept of $153M and post-divestiture revenues of $53M.
(f)	Represents all other products, including those which have lost exclusivity in major markets, over the counter brands and royalty-related revenue. Includes Plavix revenues of $45M and $44M for the three months ended June 30, 2014 and 2013, respectively, and $93M and $135M for the six months ended June 30, 2014 and 2013, respectively. Additionally, includes Avapro/Avalide revenues of $59M and $56M for the three months ended June 30, 2014 and 2013, respectively, and $115M and $102M for the six months ended June 30, 2014 and 2013, respectively.

BRISTOL-MYERS SQUIBB COMPANY

DOMESTIC REVENUES FROM OPERATIONS BY PRODUCT

QUARTERLY REVENUES TREND ANALYSIS

(Unaudited, dollars in millions)



	2013														2014										% Change
	1st Qtr		2nd Qtr		6 Months		3rd Qtr		9 Months		4th Qtr		Year		1st Qtr		2nd Qtr		6 Months		3rd Qtr	9 Months	4th Qtr	Year	Qtr vs. Qtr	YTD vs. YTD
TOTAL ^(a)	$	1,971	$	2,045	$	4,016	$	2,037	$	6,053	$	2,265	$	8,318	$	1,765	$	1,901	$	3,666					(7)%	(9)%
Virology
Baraclude	68		73		141		67		208		81		289		70		84		154						15%	9%
Reyataz	193		200		393		189		582		187		769		176		168		344						(16)%	(12)%
Sustiva Franchise ^(b)	251		275		526		259		785		307		1,092		228		266		494						(3)%	(6)%
Oncology
Erbitux	158		168		326		180		506		176		682		158		178		336						6%	3%
Sprycel	115		135		250		134		384		157		541		145		163		308						21%	23%
Yervoy ^(c)	159		140		299		130		429		148		577		146		173		319						24%	7%
Neuroscience
Abilify	328		378		706		378		1,084		435		1,519		325		417		742						10%	5%
Immunoscience
Orencia ^(d)	214		238		452		246		698		256		954		229		254		483						7%	7%
Cardiovascular
Eliquis	17		5		22		27		49		48		97		61		94		155						**	**

Diabetes Alliance ^(e)	292		320		612		308		920		322		1,242		114		—		114						(100)%	(81)%

Mature Products and All Other ^(f)	176		113		289		119		408		148		556		113		104		217						(8)%	(25)%

Total Excluding Diabetes Alliance	1,679		1,725		3,404		1,729		5,133		1,943		7,076		1,651		1,901		3,552						10%	4%



**	In excess of 100%
(a)	Domestic revenues include United States and Puerto Rico.
(b)	The Sustiva Franchise includes sales of Sustiva, as well as revenue from sales of bulk efavirenz included in the combination therapy, Atripla.
(c)	Six months ended June 30, 2013 includes $25 million of net sales that were previously deferred until sufficient historical experience to estimate sales returns was developed. The following table provides a reconciliation of the net impact of reversal of previously deferred net sales.



	2014		2013		% Change
	2nd Qtr	6 Months	2nd Qtr	6 Months	Qtr vs. Qtr	YTD vs. YTD

Yervoy Revenues As Reported	173	319	140	299	24%	7%
Reversal of deferred revenues, net	—	—	—	(25)	—	(100)%
Yervoy Revenues - Adjusted	173	319	140	274	24%	16%



(d)	Includes Orencia SubQ revenues of $105M and $82M for three months ended June 30, 2014 and 2013, respectively, and $198M and $153M for the six months ended June 30, 2014 and 2013, respectively.
(e)	Includes Bydureon, Byetta, Farxiga, Onglyza/Kombiglyze and Symlin and Myalept.
(f)	Represents all other products sold in the U.S., including those which have lost exclusivity in major markets.

BRISTOL-MYERS SQUIBB COMPANY

INTERNATIONAL REVENUES FROM OPERATIONS BY PRODUCT

QUARTERLY REVENUES TREND ANALYSIS

(Unaudited, dollars in millions)



	2013														2014										% Change		FX Impact
	1st Qtr		2nd Qtr		6 Months		3rd Qtr		9 Months		4th Qtr		Year		1st Qtr		2nd Qtr		6 Months		3rd Qtr	9 Months	4th Qtr	Year	Qtr vs. Qtr	YTD vs. YTD	Qtr vs. Qtr	YTD vs. YTD
TOTAL	$	1,860	$	2,003	$	3,863	$	2,028	$	5,891	$	2,176	$	8,067	$	2,046	$	1,988	$	4,034					(1)%	4%	—	(1)%
Virology
Baraclude	298		298		596		311		907		331		1,238		336		285		621						(4)%	4%	1%	(1)%
Reyataz	168		231		399		186		585		197		782		168		194		362						(16)%	(9)%	(1)%	(2)%
Sustiva Franchise^(a)	136		136		272		130		402		120		522		91		95		186						(30)%	(32)%	3%	2%
Oncology
Erbitux	4		3		7		3		10		4		14		11		8		19						**	**	N/A	N/A
Sprycel	172		177		349		182		531		208		739		197		205		402						16%	15%	(1)%	(3)%
Yervoy	70		93		163		108		271		112		383		125		148		273						59%	67%	3%	2%
Neuroscience
Abilify ^(b)	194		185		379		191		570		200		770		215		138		353						(25)%	(7)%	2%	2%
Immunoscience
Orencia	106		114		220		129		349		141		490		134		148		282						30%	28%	(3)%	(5)%
Cardiovascular
Eliquis	5		7		12		14		26		23		49		45		77		122						**	**	N/A	N/A

Diabetes Alliance ^(c)	66		118		184		124		308		133		441		65		27		92						(77)%	(50)%	—	—

Mature Products and All Other ^(d)	641		641		1,282		650		1,932		707		2,639		659		663		1,322						3%	3%	1%	—

Total Excluding Diabetes Alliance	1,794		1,885		3,679		1,904		5,583		2,043		7,626		1,981		1,961		3,942						4%	7%	1%	—



**	In excess of 100%
(a)	The Sustiva Franchise includes sales of Sustiva and revenue from sales of bulk efavirenz included in the combination therapy, Atripla.
(b)	Includes revenue from the co-promotional agreement with Otsuka Pharmaceutical Co., Ltd.
(c)	Includes Bydureon, Byetta, Forxiga/Xigduo, Onglyza/Kombiglyze, Symlin and Myalept.
(d)	Represents all other products, including those which have lost exclusivity in major markets, over the counter brands and royalty-related revenue.

BRISTOL-MYERS SQUIBB COMPANY

RECONCILIATION OF CERTAIN NON-GAAP LINE ITEMS TO CERTAIN GAAP LINE ITEMS

(Unaudited, dollars in millions)



	2013																					2014
	1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year			1st Qtr			2nd Qtr			6 Months			3rd Qtr	9 Months	4th Qtr	Year
Gross Profit	$	2,768		$	2,940		$	5,708		$	2,890		$	8,598		$	3,168		$	11,766		$	2,843		$	2,898		$	5,741
Specified items ^(a)	85			70			155			69			224			102			326			45			39			84
Gross profit excluding specified items	2,853			3,010			5,863			2,959			8,822			3,270			12,092			2,888			2,937			5,825

Marketing, selling and administrative	994			1,042			2,036			980			3,016			1,068			4,084			957			951			1,908
Specified items ^(a)	(1		)	(1		)	(2		)	(4		)	(6		)	(10		)	(16		)	(3		)	(3		)	(6		)
Marketing, selling and administrative excluding specified items	993			1,041			2,034			976			3,010			1,058			4,068			954			948			1,902

Research and development	930			951			1,881			893			2,774			957			3,731			946			1,416			2,362
Specified items ^(a)	—			—			—			—			—			(16		)	(16		)	(48		)	(458		)	(506		)
Research and development excluding specified items	930			951			1,881			893			2,774			941			3,715			898			958			1,856

Other (income)/expense	(19		)	199			180			5			185			20			205			(208		)	(104		)	(312		)
Specified items ^(a)	(19		)	(239		)	(258		)	(43		)	(301		)	(39		)	(340		)	88			(67		)	21
Other (income)/expense excluding specified items	(38		)	(40		)	(78		)	(38		)	(116		)	(19		)	(135		)	(120		)	(171		)	(291		)

Effective Tax Rate	7.6		%	—			4.2		%	15.4		%	8.8		%	15.4		%	10.8		%	5.0		%	25.4		%	11.4		%
Specified items ^(a)	3.4		%	13.8		%	8.3		%	2.4		%	5.6		%	2.5		%	4.6		%	18.0		%	(4.1		)%	10.7		%
Effective Tax Rate excluding specified items	11.0		%	13.8		%	12.5		%	17.8		%	14.4		%	17.9		%	15.4		%	23.0		%	21.3		%	22.1		%

(a) Refer to the Specified Items schedule for further details. Effective tax rate on the Specified Items represents the difference between the GAAP and Non-GAAP effective tax rate.

BRISTOL-MYERS SQUIBB COMPANY

SPECIFIED ITEMS

(Unaudited, dollars in millions)



	2013																					2014
	1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year			1st Qtr			2nd Qtr			6 Months			3rd Qtr	9 Months	4th Qtr	Year
Accelerated depreciation, asset impairment and other shutdown costs	$	—		$	—		$	—		$	—		$	—		$	36		$	36		$	45		$	39		$	84
Amortization of acquired Amylin intangible assets	138			137			275			137			412			137			549			—			—			—
Amortization of Amylin alliance proceeds	(67		)	(67		)	(134		)	(68		)	(202		)	(71		)	(273		)	—			—			—
Amortization of Amylin inventory adjustment	14			—			14			—			14			—			14			—			—			—
Cost of products sold	85			70			155			69			224			102			326			45			39			84

Marketing, selling and administrative*	1			1			2			4			6			10			16			3			3			6

Upfront, milestone and other payments	—			—			—			—			—			16			16			15			148			163
IPRD impairments	—			—			—			—			—			—			—			33			310			343
Research and development	—			—			—			—			—			16			16			48			458			506

Provision for restructuring	33			173			206			6			212			14			226			21			16			37
Gain on sale of product lines, businesses and assets	—			—			—			—			—			—			—			(259		)	12			(247		)
Pension curtailments, settlements and special termination benefits	—			99			99			37			136			25			161			64			45			109
Acquisition and alliance related items	—			(10		)	(10		)	—			(10		)	—			(10		)	16			17			33
Litigation charges/(recoveries)	—			(23		)	(23		)	—			(23		)	—			(23		)	25			(23		)	2
Loss on debt redemption	—			—			—			—			—			—			—			45			—			45
Upfront, milestone and other licensing receipts	(14		)	—			(14		)	—			(14		)	—			(14		)	—			—			—
Other (income)/expense	19			239			258			43			301			39			340			(88		)	67			(21		)

Increase to pretax income	105			310			415			116			531			167			698			8			567			575
Income tax on items above	(35		)	(116		)	(151		)	(40		)	(191		)	(51		)	(242		)	(179		)	(102		)	(281		)
Increase/(decrease) to net earnings	$	70		$	194		$	264		$	76		$	340		$	116		$	456		$	(171	)	$	465		$	294

* Specified items in marketing, selling and administrative are process standardization implementation costs.

BRISTOL-MYERS SQUIBB COMPANY

SELECTED BALANCE SHEET INFORMATION

(Unaudited, dollars in millions)



	March 31, 2013			June 30, 2013			September 30, 2013			December 31, 2013			March 31, 2014			June 30, 2014			September 30, 2014	December 31, 2014
Cash and cash equivalents	$	1,355		$	1,821		$	1,771		$	3,586		$	5,225		$	4,282
Marketable securities - current	1,178			978			951			939			1,834			2,893
Marketable securities - long term	3,242			3,223			3,623			3,747			3,558			3,876
Cash, cash equivalents and marketable securities	5,775			6,022			6,345			8,272			10,617			11,051

Short-term borrowings and current portion of long-term debt	(1,372		)	(764		)	(680		)	(359		)	(281		)	(365		)
Long-term debt	(6,522		)	(6,442		)	(6,532		)	(7,981		)	(7,367		)	(7,372		)
Net cash/(debt) position	$	(2,119	)	$	(1,184	)	$	(867	)	$	(68	)	$	2,969		$	3,314

BRISTOL-MYERS SQUIBB COMPANY

2014 FULL YEAR PROJECTED DILUTED EPS FROM OPERATIONS

EXCLUDING PROJECTED SPECIFIED ITEMS



	Full Year 2014
Projected Diluted Earnings Attributable to Shareholders per Common Share - GAAP	$1.50 to $1.60
Projected Specified Items:
Downsizing and streamlining of worldwide operations	0.18
Upfront and milestone payments, net	0.13
Gain on diabetes business divestiture and other related impacts	(0.28	)
Pension settlements	0.06
Impairment Charges	0.13
Other	(0.02	)
Total	0.20

Projected Diluted Earnings Attributable to Shareholders per Common Share - Non-GAAP	$1.70 to $1.80



Gross margin as a percentage of revenues on a GAAP and non-GAAP basis for the six months ended June 30, 2014 was 74.6% and 75.6%, respectively. On a non-GAAP basis, the Company projects gross margin as a percentage of revenues for the full year 2014 between 75% and 76%. There is no reliable comparable GAAP measure for this forward-looking information on gross margin. See "—Reconciliation of GAAP and non-GAAP Growth Dollars and Percentages Excluding Foreign Exchange Impact".

Research and development expenses on a GAAP and non-GAAP basis for the six months ended June 30, 2014 were $2.4 billion and $1.9 billion, respectively. On a non-GAAP basis, the Company projects research and development expense for the full year 2014 to grow in the mid single digit range compared to 2013. It is estimated that 30% to 45% of the research and development expenses in 2014 will be incurred on late-stage development programs. There is no reliable comparable GAAP measure for this forward-looking information on research and development. See "—Reconciliation of Certain non-GAAP Line Items to Certain GAAP Line Items".

Marketing, selling and administrative expenses on a GAAP and non-GAAP basis for the six months ended June 30, 2014 were $1.9 billion. On a GAAP basis, expenses for the six months ended June 30, 2014 included specified items of $6 million. On a non-GAAP basis, the Company projects marketing, selling and administrative expenses for the full year 2014 to decrease in the mid single digit range compared to 2013. There is no reliable comparable GAAP measure for this forward-looking information on marketing, selling and administrative expense. See "—Reconciliation of Certain non-GAAP Line Items to Certain GAAP Line Items".

The effective tax rate on a GAAP basis for the six months ended June 30, 2014 was 11.4%. On a non-GAAP basis, for the six months ended June 30, 2014 the effective tax rate was 22.1%. On a non-GAAP basis, the Company projects an annual effective tax rate of approximately 18%. There is no reliable comparable GAAP measure for this forward-looking information on the tax rate. See "—Reconciliation of Certain non-GAAP Line Items to Certain GAAP Line Items".

The GAAP financial results for the full year 2014 will include specified items, including gains on divestitures, expected charges associated with downsizing and streamlining worldwide operations, asset impairments, milestone payments, restructuring, charges and recoveries relating to significant legal proceedings, and pension settlements. The GAAP financial results for the full year 2014 could also include other specified items that have not yet been identified and quantified, including any gains or losses from acquisitions or divestitures, additional upfront, milestone and other licensing payments, charges for in-process research and development and licensed asset impairments, charges and recoveries relating to significant legal proceedings, restructuring activities and significant tax events. For a fuller discussion of certain litigation and other matters that could impact full year GAAP results, as well as the use of non-GAAP financial information, see Bristol-Myers Squibb Reports Second Quarter 2014 Financial Results, July 24, 2014 including “2014 Financial Guidance” and “Use of non-GAAP Financial Information” therein.

GRAPHIC 4 bmslogo.jpg GRAPHIC begin 644 bmslogo.jpg M_]C_X``02D9)1@`!`@$`M`"T``#_X0I)17AI9@``34T`*@````@`!P$2``,` M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q M``(````<````<@$R``(````4````CH=I``0````!````I````-``&W=````G M$``;=T```"<0061O8F4@4&AO=&]S:&]P($-3,B!7:6YD;W=S`#(P,#`1L`!0`` M``$```$F`2@``P````$``@```@$`!`````$```$N`@(`!`````$```D3```` M`````$@````!````2`````'_V/_@`!!*1DE&``$"``!(`$@``/_M``Q!9&]B M95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\, M#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P, M#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P, M#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`%0"@`P$B``(1`0,1`?_=``0` M"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!`0$!`0$` M`````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$% M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F M]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B M$P4R@9$4H;%"(\%2T?`S)&+A7U5F9VAI:FML;6YO8G-T=7 M9W>'EZ>WQ__:``P#`0`"$0,1`#\`[[K-K+A]E=><:EKF-M>';"YSR-M&Z1[& M5.]?)9_H_2_,]546O%=(;96`^H.9=4&!UWK--5=5--[MSO3RO5]1CWLMNV?S M=W^B)Z.5BY.1NM?O?:Z'5L;8XMM=OQZW?:/?779/I-V/^Q^I79ZGV?TUG6X[ MVY#KI:*ZG[?6W.;L:STJ[:Q75^B]+?97ZCZJ_2I_T=U?JJS`"JO3=JSD;NM= MG6Z.XX=C\=UWJLWBNUN\O%5KFL<-FXNCZ7\Y^EK]%;^4]M>+=8\D-96YSB`28`)/M8'.=_94>0:@[D[LN,T"-A'; M^7]5P<7ZUY-F/TW.R<%M6%U:YE%+V7>I8Q]F[T/6I=32S8_9[O3OL]-;F=DN MQ,2W);1;E&H;A10`ZQW\FMKW5M<[^VN#Z=?C?LCZOV=.O];K=-E57V0/-H;6 M269GJX;B]F'MHW>IF,JIM_X;](CV_9_^;'7>H59ES\BNW+HHM^U6NVU^MNQJ MZ_TNW](UM>S_``ES'_Z.Q2RPQXA0X?5PUK^]PK(Y36IXM+O_``;>[''@@8.= MC=0Q*LW%<7X][=U;R"V6_O;7AKURS\G%L^LX#F[-T#MWXNG^"N.;6@!6HW>TOZDZGK&+TTT MRW+JMM%^X0#2:]U?IQN_PS$#KO76]$&+==3OQ;[A3=:'0ZH$.L];TMCO4J8R MNQ]OO]BY_IF9D6=0Z3-GJV^GU/[`'7_IZJO9;Z?J6TU^ MK^D6EU&RRW(Z5B];&-6[(R[:_1KL<]KZGXF50=WK5X[_`'W7-I^C_A:O\)8E M[0$HV+%2XAUEP\?_`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`O7JNE]3/4'9K35Z)PLI^+](.W;&UV>KH!LW^ MK]!1Z1U4]2;EDT^@<3*MQ2-V[<:MOZ30-V[]WT5R.1D4EO5A@W?Y<'5_\GU, M>1:23BLM/H3[\9S&7_:'V,^S^DS])_-I5WX[OMS<.Z>LCK;OL55;SO+'6TG( MEU7]7^M_<6>]*XC?>_ZW_H?]5__]#T M#K?JPPXA_6Q!`@06[F[66.)_1[KMGV>S;9^D_P`%Z?K+.QW/]"D-K_0^@[:X M/'HBGV_;/48ZK>[]+Z7VGU'_`&OU/Z+^B]=?/:2L8_D%UNULGSFKVZ;;_P!9 M^C?J_NW`Y6EI8/L[.0&;:MTV>UUE_I?9OIU5_H?_`$)6ZOE5)1Y?G/\`(?X+ M+A^0?RE_A/U3I/GW3KY524;(_5.D^:1CNOE9))3]5)+Y5224_52S.F>C^T^I MR;CE^I7ZGK``>CL_5?LGIRW['N^T_P#"_:OM?J+YH23H[2WV_P"ZZK3O';?] MG1^J=)\^Z6B^5DDU<_529?*R22GZ.Z4,?_G'UCTW7&^,?[0'BL51L=]F^SNK M<;OYK?ZGJK<7RJDGY-Q=_+'?^[X+,>QV^:6W][^7$_5.D^:6D^:^5DDQ>__9 M_^T/'E!H;W1O.$)) M30/S```````)```````````!`#A"24T$"@```````0``.$))32<0```````* M``$``````````CA"24T#]0``````2``O9F8``0!L9F8`!@```````0`O9F8` M`0"AF9H`!@```````0`R`````0!:````!@```````0`U`````0`M````!@`` M`````3A"24T#^```````<```_____________________________P/H```` M`/____________________________\#Z`````#_____________________ M________`^@`````_____________________________P/H```X0DE-!``` M``````(``#A"24T$`@``````!``````X0DE-!#````````(!`3A"24T$+0`` M````!@`!`````SA"24T$"```````$`````$```)````"0``````X0DE-!!X` M``````0`````.$))300:``````-!````!@``````````````5@```HP````& M`&(`;0!S`#,`,``Q`````0`````````````````````````!```````````` M``*,````5@`````````````````````!`````````````````````````!`` M```!````````;G5L;`````(````&8F]U;F1S3V)J8P````$```````!28W0Q M````!`````!4;W`@;&]N9P``````````3&5F=&QO;F<``````````$)T;VUL M;VYG````5@````!29VAT;&]N9P```HP````&7!E`````$YO;F4` M```)=&]P3W5T```"=@```)$P`8``'_V/_@`!!*1DE& M``$"``!(`$@``/_M``Q!9&]B95]#30`!_^X`#D%D;V)E`&2``````?_;`(0` M#`@("`D(#`D)#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P, M#`P,#`P,#`P,#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P, M#`P1$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@` M%0"@`P$B``(1`0,1`?_=``0`"O_$`3\```$%`0$!`0$!``````````,``0($ M!08'"`D*"P$``04!`0$!`0$``````````0`"`P0%!@<("0H+$``!!`$#`@0" M!0<&"`4###,!``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,' M)9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34 MY/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08' M!P8%-0$``A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`[[K-K+A] ME=><:EKF-M>';"YSR-M&Z1[&5.]?)9_H_2_,]546O%=(;96`^H.9=4&!UWK- M-5=5--[MSO3RO5]1CWLMNV?S=W^B)Z.5BY.1NM?O?:Z'5L;8XMM=OQZW?:/? M779/I-V/^Q^I79ZGV?TUG6X[VY#KI:*ZG[?6W.;L:STJ[:Q75^B]+?97ZCZJ M_2I_T=U?JJS`"JO3=JSD;NM=G6Z.XX=C\=UWJLWBNUN\O%5KFL<-FXNCZ7\Y^EK]%;^4]M>+=8\D-96YSB`28`)/ MM8'.=_94>0:@[D[LN,T"-A';^7]5P<7ZUY-F/TW.R<%M6%U:YE%+V7>I8Q]F M[T/6I=32S8_9[O3OL]-;F=DNQ,2W);1;E&H;A10`ZQW\FMKW5M<[^VN#Z=?C M?LCZOV=.O];K=-E57V0/-H;6269GJX;B]F'MHW>IF,JIM_X;](CV_9_^;'7> MH59ES\BNW+HHM^U6NVU^MNQJZ_TNW](UM>S_``ES'_Z.Q2RPQXA0X?5PUK^] MPK(Y36IXM+O_``;>[''@@8.=C=0Q*LW%<7X][=U;R"V6_O;7AKURS\G%L^LX M#F[-T#MWXNG M^"N.;6@!6HW>TOZDZGK&+TTTRW+JMM%^X0#2:]U?IQN_PS$#KO76]$&+==3O MQ;[A3=:'0ZH$.L];TMCO4J8RNQ]OO]BY_IF9D6=0Z3-GJV^GU/[`'7_IZJO9;Z?J6TU^K^D6EU&RRW(Z5B];&-6[(R[:_1KL<]KZGXF5 M0=WK5X[_`'W7-I^C_A:O\)8E[0$HV+%2XAUEP\?_`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`O7JNE]3/4'9K M35Z)PLI^+](.W;&UV>KH!LW^K]!1Z1U4]2;EDT^@<3*MQ2-V[<:MOZ30-V[] MWT5R.1D4EO5A@W?Y<'5_\GU,>1:23BLM/H3[\9S&7_:'V,^S^DS])_-I5WX[ MOMS<.Z>LCK;OL55;SO+'6TG(EU7]7^ MM_<6>]*XC?>_ZW_H?]5__]#T#K?JPPXA_6Q!`@06[F[66.)_1[KMGV>S;9^D M_P`%Z?K+.QW/]"D-K_0^@[:X/'HBGV_;/48ZK>[]+Z7VGU'_`&OU/Z+^B]=? M/:2L8_D%UNULGSFKVZ;;_P!9^C?J_NW`Y6EI8/L[.0&;:MTV>UUE_I?9OIU5 M_H?_`$)6ZOE5)1Y?G/\`(?X++A^0?RE_A/U3I/GW3KY524;(_5.D^:1CNOE9 M))3]5)+Y5224_52S.F>C^T^IR;CE^I7ZGK``>CL_5?LGIRW['N^T_P#"_:OM M?J+YH23H[2WV_P"ZZK3O';?]G1^J=)\^Z6B^5DDU<_529?*R22GZ.Z4,?_G' MUCTW7&^,?[0'BL51L=]F^SNK<;OYK?ZGJK<7RJDGY-Q=_+'?^[X+,>QV^:6W M][^7$_5.D^:6D^:^5DDQ>__9`#A"24T$(0``````50````$!````#P!!`&0` M;P!B`&4`(`!0`&@`;P!T`&\`G)E4WI.5&-Z:V,Y9"(_/@H\ M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2(S M+C$N,2TQ,3$B/@H@("`\"UN&UL;G,Z&%P+S$N M,"]S5'EP92]297-O=7)C95)E9B,B/@H@("`@("`@("`\>&%P34TZ1&]C=6UE M;G1)1#YU=6ED.C5#-3A&,3`W0S8P,T1#,3$X,3&%P34TZ26YS=&%N8V5)1#YU M=6ED.C5$-3A&,3`W0S8P,T1#,3$X,3&%P34TZ1&5R:79E9$9R;VT@&UL;G,Z>&%P/2)H='1P.B\O M;G,N861O8F4N8V]M+WAA<"\Q+C`O(CX*("`@("`@("`@/'AA<#I#&%P.DUO9&EF>41A=&4^,C`P-RTP-2TQ-E0Q,3HU-CHS M."TP-#HP,#PO>&%P.DUO9&EF>41A=&4^"B`@("`@("`@(#QX87`Z365T861A M=&%$871E/C(P,#2\^"B`@("`@(#PO&EF/2)H='1P.B\O;G,N861O8F4N8V]M+V5X:68O,2XP+R(^"B`@("`@("`@ M(#QE>&EF.E!I>&5L6$1I;65N#IX;7!M971A/@H@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`* M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`* M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`* M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@ M("`@("`@("`@("`@("`@("`@("`@("`@(`H\/WAP86-K970@96YD/2)W(C\^ M_^(,6$E#0U]04D]&24Q%``$!```,2$QI;F\"$```;6YT`",`*``M`#(`-P`[`$``10!*`$\`5`!9`%X`8P!H`&T`<@!W`'P`@0"& M`(L`D`"5`)H`GP"D`*D`K@"R`+<`O`#!`,8`RP#0`-4`VP#@`.4`ZP#P`/8` M^P$!`0&!YD'K`>_!]('Y0?X"`L('P@R"$8(6@AN"(((E@BJ M"+X(T@CG"/L)$`DE"3H)3PED"7D)CPFD";H)SPGE"?L*$0HG"CT*5`IJ"H$* MF`JN"L4*W`KS"PL+(@LY"U$+:0N`"Y@+L`O("^$+^0P2#"H,0PQ<#'4,C@RG M#,`,V0SS#0T-)@U`#5H-=`V.#:D-PPW>#?@.$PXN#DD.9`Y_#IL.M@[2#NX/ M"0\E#T$/7@]Z#Y8/LP_/#^P0"1`F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&, M$:H1R1'H$@<2)A)%$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4 M:A2+%*T4SA3P%1(5-!56%7@5FQ6]%>`6`Q8F%DD6;!:/%K(6UA;Z%QT701=E M%XD7KA?2%_<8&QA`&&48BABO&-48^AD@&449:QF1&;<9W1H$&BH:41IW&IX: MQ1KL&Q0;.QMC&XH;LAO:'`(<*AQ2''LP>%AY` M'FH>E!Z^'ND?$Q\^'VD?E!^_'^H@%2!!(&P@F"#$(/`A'"%((74AH2'.(?LB M)R)5(H(BKR+=(PHC."-F(Y0CPB/P)!\D321\)*LDVB4))3@E:"67)<`^(#Y@/J`^ MX#\A/V$_HC_B0"-`9$"F0.=!*4%J0:Q![D(P0G)"M4+W0SI#?4/`1`-$1T2* M1,Y%$D5519I%WD8B1F=&JT;P1S5'>T?`2`5(2TB12-=)'4EC2:E)\$HW2GU* MQ$L,2U-+FDOB3"I,%W)7AI>;%Z] M7P]?85^S8`5@5V"J8/QA3V&B8?5B26*<8O!C0V.78^MD0&249.EE/6629>=F M/6:29NAG/6>39^EH/VB6:.QI0VF::?%J2&J?:O=K3VNG:_]L5VRO;0AM8&VY M;A)N:V[$;QYO>&_1<"MPAG#@<3IQE7'P,QY*GF)>>=Z1GJE>P1[8WO"?"%\@7SA?4%]H7X! M?F)^PG\C?X1_Y8!'@*B!"H%K@%JX8.AG*& MUX<[AY^(!(AIB,Z),XF9B?Z*9(K*BS"+EHO\C&.,RHTQC9B-_XYFCLZ/-H^> MD`:0;I#6D3^1J)(1DGJ2XY--D[:4()2*E/257Y7)EC26GY<*EW67X)A,F+B9 M))F0F?R::)K5FT*;KYP0)ZNGQV?BY_ZH&F@V*%'H;:B)J*6 MHP:C=J/FI%:DQZ4XI:FF&J:+IOVG;J?@J%*HQ*DWJ:FJ'*J/JP*K=:OIK%RL MT*U$K;BN+:ZAKQ:OB[``L'6PZK%@L=:R2[+"LSBSKK0EM)RU$[6*M@&V>;;P MMVBWX+A9N-&Y2KG"NCNZM;LNNZ>$;R;O16]C[X*OH2^_[]ZO_7`<,#LP6?! MX$?PMO#6,/4Q%'$SL5+QHM\IWZ_@-N"]X43AS.)3XMOC8^/K MY'/D_.6$Y@WFENV<[BCNM.]`[\SP M6/#E\7+Q__*,\QGSI_0T],+U4/7>]FWV^_>*^!GXJ/DX^H6&AXB)BI25EI>8F9JDI::GJ*FJM+6VM[BYNL3%QL?( MR'EZ>WQ]?G]TA8:'B(F*BXR-CH^#E)66EY MB9FIN]^Z] MT4OYL_)FE^*7Q_W3V11X]-P]@92:DV-TYLH$&IWQVUNL346SL!%%J4O1PU*O M75[`KXL;1U$EP5'L8\B?0'] MQ.<$Y)Y7O=WCB\7='(AM8?.:YEJ(D`]`:N_I&CGRZUMM_P#R'^2WRB^-G2/R M:Q_R8[AZ,WOTS5[+ZI^9^V=I]E=C[0V#_=?LBB@SO1OR=R>V.L-R8*3&;*WC M!G*:'<&0Q,?W4`FD>&GD7'&&3*';N6N5N4^:-^Y5DY5LMPL+Y9;C;'D@@DF\ M2`E+JQ62='U2QE&,*2'2:`,P,M1B/NG-7-_.?*/+O.,7.%_MNX[>T5MNT<5Q M/%!X=P`]GN#1V\B:8I0ZB=XQJ6I*J1%I)P.M]K[$I]YXCI_YN3.5.5=XV2/^T";5"EY;^HN;6NM=/`R1AHS0FJCH>;19[:FX0;#S MUSESAL>_RXB+[Q.]E<^AM+RFA]6"(I"DHJ%HQSU8D/Y:.#(!'S=_F5$$`@CY MH=@D$'D$$4UB"/<:?ZZ=Q_TP7*W_`'+(?\_4K?ZT%M_X47F__N;3_P";KW_# M:&$_[S<_F5_^EH=A?_4WOW^NG/\`],'RM_W+(?\`/U[_`%H+?_PHO-__`'-I M_P#-T7+Y%=`_&SXK[>H\YW)_,5_F/X2NS4JT>T-DXOYD]D[A[%WYE99!!38? M9&QL125.X=Q5U35ND(:&'[>*1U\TL:G5[$W+/,7-'-UR]OLGMGRQ)'&*R2MM ML"0PKQ+2RL0B`#.34@'2#T$^;.6.4>2K6.YW_P!U^;8Y)#2*%=UG>>9N`2&% M07D)-!@:02-1`SU6ME>NOE_O3OOI?K_#?(CYN_%[9&]J?,=G;EV]W%\P>S-\ M=X[;^-.R915;Z[J[A@Q^?QFR.EVVV"*U>^EQ%:VQ*-+=$?VDTG8BQ@:`2XI$,^T\^;AS M/R]M=OS7S'LVW7(:XDCNMTN)KR/;X[Y^7':G3V^L-D]N],;[J,5%\/L]N".7^(5]%MC95#F%P6Y\O7O-E\AN7M M?89CWC0G(2O.5^YA$DA,8$<^X?M-;\OWSI+OEN&_>2)\(,DI77&HHH M2WFK;/H%/A:@SU*/ME[S77,W/6];#N5N\7+UR5_=;O74PCA5]$CM5FDN8:72 M:R3\:U..KX/>/?62_7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^ MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7 MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z] MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O? MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U M_]#?X]^Z]U[W[KW5++R2_-OO_O3Y&SN]9\ M-[D[CIT(--DL7LFC*[>PE0OF@>WN+W^ M*&S$BM;6Q\U:4_K2K@@:48$$=8]DGW%YHYDYL8ZN4N7K>ZM;'^&>],3+=70\ MF6$?H0MD$ZG4@@]%"V[U[B^I/AK\'/FK4;=.Z.I,M\5MA?&CYX;$2EGJZ?>/ MQCWSCH\3C>P)<=2*9*K-=.9[*"=YD4U3XFHDC$D44)/L:7.Y3;SSOS]R*MSX M6\IN\U]M,M0#'?1-J:'4>"W*+0`]HD4&A+=`.TVJ'8N0/;CW#:T\;8GV2';] MYAH2)=OF72L^D<7M7:I([C$Q%0J]'D^'5+M'=^U.T?Y:7R?QVV^Z8NCL3A,O MU/E-Z4F/W%C>\/B1NI7/3?8N.EEC>GJLSLBED&`KJRB(:BJJ:F:.8RN7]@#G M9[RRO-I]TN4Y9;$[@[+<+$61K7<8_P#;9)_N+.I."\(_1=D^!E0AJFO2AD^/?RV^$]\I\.= MV5?R/Z"QX,E5\0>\MVS'>.T\5#JD>B^/O>&6%57TJ1(0E-A-RM544<:$1U'D M<63#F3DWGO\`1YVLQM?,3<-QM8QX-K8 MC)9'9W;'R0^3.*QLU;UWO;#.M'NW9'6G4N&RV1.^MZ;5R(DIIJNOJ(\3#4QM M'*BDJ_M;<RL68":)LQRSW#*OA12+1@J`R%352;`VU64;M%_LJHQN.I):RNQVU/O& M;'[,Q,S`TV/Q&&BIS)Y(J8M.='L/[CS=S3S_`'>V\H[/;1VFT2S+'!86J^'` M&)H&DIF5A\3R2DTH7HN>A+MG)?*'MO9[ISKOEU+>[W#`\EQN-VWBW!5025BK MVQ*?A2*(+6H2K8ZJUH=J=F_)S=M-U?N5,CM[OO\`F.G&]W_*"6FEE&4^,W\N M'95>M)U?T935/HEP6Y>U('CHZK0D;5%=D*W[N`A1)[EJ2\VKE2S?=K4K)R[R MQJM;"H[;[>I16>[(X.EN:LN31$CT-FG4,1V6\!XN9N;=-YN-#W;?L M,+4M[,'\$ER*(U`-3O)K7%>A9J?BE2]X]V_S1NL^KY:3KSL+IO?/P@WY\8-P M8I(J"GZU[.ZL^.-*.O/X>`C046%J*2F.(JU*.HQ]5(=+,JV)UYO?8-A]IMUW M8&YVV^M]TAOT;)G@N+T^-7S+`GQ%X=ZC-">CMN24YDYB]Y]GV8K:;KM]SM$V MW.M%%O<6U@/`T^00@>$V"-#'!('5LGPW^2-)\INAML=E3XMMK[ZH*K)[%[AV M%4!XLAUWW#LNI_@V_P#9U?32LU13?8YB$S4HD_UK-XNWL%EMIA\,UM*-4,@/`U7#4P'##RZG#D#FU.=.6;/=VA\'_=>Z][]U[IHSFX" MHI8G[``3TQJ/DANX*_\`5SH4>O\`O'I;MC_F5W;O6/8Y$1F*;$WYM;=LBP@7 M:5X\#E:^1$4?4D`#V4;EL&^[/_R5MEN[7-/U8I(\_P"W4='.U\R]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U'K*RDQ]+4UU?54]#0T M<$M35UE9/%34M+30(9)JBIJ)F2&""&-2S.Q"J!HF&S>&W'BZ/.;>R^,SV%R,7GQ^7PU? M293%U\`=HS-1Y"AEGI*J+R(5U(["X(^H]WG@GM97M[F%XYU-"K`JP/H0:$?F M.J6]Q;W<,=S:SI+;N*JR,&5AZA@2"/L/3G[:Z>Z][]U[KWOW7NO>_=>Z][]U M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO> M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NFG-Y[![:QM1 MF=QYK$[?Q%(NJJRN;R-'BL;3+SZJBNKYH*6%>/JS#V]!;W%U*L%K`\DQX*JE MF/V``D],7%S;6<+7%W<)%`O%G8*H^TL0!^WH'J3Y2_&2OK4QM#\C.B*S(RRF M"/'TG;O7]16R3`Z3"E+#N%YWE#<:0M[^SM^4N:XXS+)RSN"Q`5J;:8"GK4I3 MHA3G3DZ600Q\V;8TI--(NH":^E`]>E/O?NWISK5=J/V%VIU[LE-]9BDV_LMM MT[PP.#&Z\U7ND5)C=OG(U]/_`!:JGDE4!8-?+"]KCVDL-AWO=#>#;=HN9S;H M7E\.-W\-1Q9](.D#YTZ6;CS%L&T"R.Z[U:VPN9`D7B2HGB.W!4U,-1..%>/0 MH>RGHYZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][ M]U[ICGW-MNESU#M:IW!@Z?<^3I*BOQNW)\M00Y[(4-(":NMH<1)4+D*NDI0# MY)(XV1+U"VMT]O)=I;2&T0@,X4E%)X`M2@)\@34])FO+1+F.R>ZC%XZEE MC+*'8#B0M=1`\R!0=/GM/TIZ][]U[KWOW7NF-MS[:7<$>TFW#@UW5+CWRT6V M6RU`-P28J.00R9./#&H_B+X^.5@K3",QAC8F_M1])=&V-X+:3Z,-IUZ3HU<= M.JFFORK7I,;RS%T+$W4?UI34(]2Z]/#5HKJTUQ6E.GSVGZ4]>]^Z]U[W[KW7 M_]'?X]^Z]U7S_,"[DWO@=G[)^-'1>0^U^27RWS==UAUU7P:I)>O-FQ4:U/;7 M=%?'$Z3PXWKC9TTDD,B,LG\2J:;QARI7W)'MQLEA<7M_S3S!'7E?9HQ/,#_H MTM:6]L/(M-*`".&A6K2M>HM]T=_W&UL-NY0Y:ET\W;[(;>!AQ@B`KF=D?'GXBY'I3KC'C&[,ZXZ3W1MO#Q,$^YJ_MMK962OS& M2D156IS.>R9I&VIV]7=B7<^;,3Y]`U_+PVW@= MY?RV/BYM'=6)HL]MG=/QKVEMW<6$R4(J,?F,'FML_P`.RN,KH&],U)74-2\4 MB_E&(]GGN5=7%C[H\VWMI,T=U#NDCHRFA5EDU*P/D00".@_[56EMN'M%R987 ML"RV*WMGH&2 MJE;^+?*'^6AO?(-1[YZGJ9U!?-[BZAITDH8BR.*2LQ]*:2$O+K]S'#=[3S5: MK?W)2+EKFJEO>4^&PWR):Q7`'X4N31SGN5WUM04Z@Z>SWGD^\;;K37-S5R?6 MYLJ_%N/+\S4FMB?QR6HJ@J#I=$T+5J];%W5W9>S>Y>N=D]K=>Y>+.[)[!VUB M=U[:RL5E^YQ68I(ZN!:B(,S4M=3:S%40-^Y!.CQN`RD#&;=MJOMCW._VC

U3B7;KJ%9(V'FK"HJ/(C@ MP.58$'(Z(1_R_YD_P#(/_Q>?Y??^_;RON0_=O\`Y+7+?_BO[=_VCKU&7LM_ MR0>:?_%DW3_M;H`_GSW-LGM'M?)=/[SR/C^?PQP6#^3?S;KX2DM+O/YW,&W;UOV`VCOCY-=Z8X4GR2^7&;H>S>P<=-JDEZXV1 M#1?:]2=8^29(YX<;USLZ6-)XV59/XE4U`D+E%;V$O&A5I2I'0T]KN7]QM;'DC\2/^R_OYJ7_`(>?Q_^![@]K.L.](E#)B M.N?DK34[474_:TRC_)L7B>S:"-\!F9[11"O2GJJF4LRCVKVL_P!?>0[C8'[N M:=A1Y[0_BFL2:W%N/-F@/ZT0R=&I%%`>D>[C_6Y]Q+;F1.SE#F.1+>\'X8-P M`I;7)\E6X6L,IP-81W-2.K7?]^Z]U[W[KW7O?NO=$R^>=5\QZ?X] MYU/@UC=I5W=E7DJ2F-3NBLQ=-5X?:K4>1ER^3V?!N!?[LY#=Z545-%319)A2 MB6632\B1H1Q[>IR2W,EN>?Y9EV$32,,0TE5TK(4[Q'346=U0!@$GJ/_QM_]E[MJ,D],6WEN/+9ZH@KWG--]E04E=52TN-19CXT@ITBB3]J!Q[Z9;1 MLNP;!9+%LFV6UK9A:_I(J`BE:D@5;&:DDGS/7#>]^YCYDOFFW_=KJ\OB]/U M9&-3 M)X3I'&C$5(#&[$<:F;NI72M:"IO^9[_1W-_+NH]M?(7H3LC>&YNI6W)28 M6JRM?-'B.Q^K-S5OFDP%14YW;2XNGR>&RK0/#%D((&2FJ_'#(C&:.1IB]J/ M>2T]RWNN6^8MK@BWGPBP4#5!<(:P$?459:U$N&6K`X($(>\GL9>>U,=GS5 MRQN]Q-L?C!"S'3/;2&N@EX](9&H0'"H5:BD'4";2_P"1I_-[(^0N;R7Q-^1 MNX)]X[^P^VJS<_5?9.4=7W%NG"X1H1G]H;LJ@%;,YW$44ZUE'7N#4U-)#4BI M=Y(D>2)/?[VDVOEJ"+G'EBV$&W/([B!?@C9_@DC'X48C2R?"K%=(`)`FC[M M_O1NW-5Q-R/S9=&XW2.$R6UPW]I(B4UQ2G\;J#K1SW,H?625!.R][Q9ZR^Z] M[]U[KWOW7NJ-/YS?\S;M/X&8KJ79726WMO3[_P"UHMRYNHW?N_'3YC#[;V]M M:HQ-&]+C,/'4T5/DQWM5M'N'-O-]OUS(-NL MRBB.-@K.\@8U9J$JBA>`%6)X@0<;_O`^\6]>V<.Q[=R[:Q'=+X2.995+)&D M9445:@,[%N))"J/A)8$"S_)^_F"[[^??2&]\UVIMO"X;L?JO=E!MC/9?:]+5 M4&V]U4&9Q1R>'R]-CZJHK&Q>6C^WGAK>.:2$%(Y4T+-XHR;WI]M]O\`;K?K M"#:+J23;+R$R(LA!>,JVEE)`&I<@J2`>(-=-2>>PWNEN?N?RYN-QO5I''NUE M.L;M&"L]^Z]T#G=WR#Z4^-^ MSJC?O>796U.M=K0"015VY,E'3U.3J(E#M08'$1";,;AR95@5I:&GJAAR$M[ M.]AY;WWF>]7;M@VN:ZNSY(M0H]78T5%_I.0/GT0V.M:_% M5Z:X)9#)TU'D**=2"DD4T4]^Z]U[W[KW7%]>A_'I$FEO&7!!['3K"D,5U?6QO;WL4J\.M&M#3CUHD M?SFLW_,?V)V1@=C?+GO#!;EV/V'C,GN;9.T.E\EF[:5N3I6[$V'%S[Q> M]_@![J\R4'X;?_M'BZRX^[>2?9[E:I_%<_\`:3-U;=[AOJ<^O>_=>ZK,_F)? MRXL5\\Q;'N^WSV=WM<#V5Q$592BY5Q0^6#0X(R#D9ZY@67,/,&R[G;WUE MN]Q'?6TP96$CX9&J//(J,@X(P10]?1_^%/RBVQ\QOC5UEWWMO[:FGW5A4I=W MXGE\AVMOW#VH-W[J1[H)('M;MVWW>[;A9;980F2]N)5CC4>;N0JC]I MX^7'I!NFY66S;;?[MN,PCL+:%Y9&/!412S']@P/,X'7S6OE9\PNV?E#\@.S> M[,SNW=F)AWGN6NJMN;:I]QY6@VEM"GD^TVMMB@IZ>L6D@CQ&$@ACE:)56>I M\D[`OQ/4;E#DK9^4^7-JV&"SA=H(@'MF[^2K_+G4[Z#^> M^[^_>U\KNK-4V]2M:%#2PK M.T2D.(B9,5/?7W-/U_,7MW9_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_ M=>Z][]U[HO7RO^0FW_BI\=.VOD#N2D.2H.M-IU.8I<.LPIFSN?JZBFP^UL` MDJ_VPSFY>A% M9J>=>?05YWYIM>2>5-\YHO$UQ6<_>_//%GM=WNC2WMR[%59F6VMHE!9BL8J%1%!X`NYH"6=JF M]N'_`(3(]8_W5CIZCY5;\_OM]FOERT/7>W_[JC(>/U&/;SY[^+M1B;@`Y,.5 MYN#Q[Q];[U>Z_5EEY0M_H-7PF9_$T_Z?1IK_`,VZ=9K]SO9_H@KJE?^&5ZH/^>7\O7Y(?`#=^VZ'LRICW3L'5$L76?:^UY\A)M>O MJ)OO7PS4];:KVEN>D11.]!+Z74-)3RU"([KD1[>>Y/+'N-974FU)X.XH/U[ M>0+X@!QJJ,21GAK'#@P4D`XR>YGM9S;[7W]I'O#B;;'-+>YC+>&Q&=%#F0? M$4/')1F`)'T"_C7VA3=U_'OI'MREF6=>Q^J]B;PG=23HK\[MO'5V3IWOR)J3 M(RRQ.#R'0@\CWSCYIVEMBYDW[9G6AM;R6,?8CL%/YK0CY'KJ+RAO_=>Z][]U[KWOW7NO>_=>Z] M[]U[I`]K;_H>J.K^Q^TS'9]NDWC=MLVF14ENKB.(,>"F1P@)^0)J>BS>]TCV39MVW MF:)GAM+:69E7XF$2,Y4?,A:#K4^^)'\_WY-]G?+KKK8?:VR>N:KJ/N#L?`]? M4NVMHX'4FY-C'>F=I<%MW(XK/2Y:JGS\F)K^$UJ54#?=PB0Q+`Y0+F#SE] MW/E7:N3-SW#9[^Z&\V5J\Q>1U2^$A=U9-(":@#ITGM-ZA7K"'D7[T'..\\ M][3MF][=:-L5_=I`(XD820^X2-E?42^DL-88'4Z0II2^?^9/A?G9E>EIZK MX1]C]>=<5V"PV\,[V37;EAGCWSD\+BL3!7XW&];YB?#9W`X;)3)35BSRU4=/ M+K:`PU4&F1CCU[73^W\.^JG/FV7-U'(\:0!"/"5F8AFG4,CLHJM`I84U:D;' M63/N[;^Y4_+S/[=;M:VDD4I8:Z=+KGK4`_E%[Z MWKV'_-8^.&\=^[NW-O/=F:S_`&#+EMR[ISF3SN=R3R=3;^#_`'N4R=34UM2I M5B-+N5"\`6X]YI>\VWV&V^T/,]EMUE%!9QQPZ4C141?\8AXH`'[.L#O8K]^Z]U5I_-0Q_S M[?I/[B^%W9FP^N,%LO9F^-V]M2UT=52]JYC%[?Q\.7@HNM\Y/ALUAL5,NH M:TR&]!6M.8A#5("WN6_:.3VZ&_0VW/.U7%U<3SQ1V]&W5G8J3.@968:BM/C M6E=2'J%_>J+W//+L]W[>[Q;6EM;V\TMR347+JBA@+=RCHITAZ_`Y.G2XSUJX M_P`CW=NZMZ_S2^L=S[QW+G]V;DS6V.WZC,;@W)F,CG,UE9VZTW(YER64R=14 MUM=(60&\KL;@?T'O+/W\L[2P]I-UM+&UCAM8Y;8BJ*H\=/A50`/R'6&7W< MKZ]W'WHV>\W"\EGNY(;HN\CL[L?IY,LS$D_F>M]GWSQZZ:]>]^Z]U[W[KW7_ MTM^+/9W#;7P>9W-N+)4>%V_MW%9'.9W,9&=;'XK#XFDFK\GDJZID(CIZ.AH MJ=Y978@BDGZ>WK>WGN[B"UMHF>YE=410EF8@H'F22`!Z],7-S;V5M<7EW M,L=K$C.[L:J"S,3Y``$D^0'5:GP7P.8^0?8?8W\Q;L/&5E%-W#CAUW\6MM M9B%XJO87Q8V_E)G#9O[.=5DQV?[MST3;AK@=9%(:18Y#$Q42E[@7$'+>V[9 M[9[;K+9-XU^ZG$U^ZT9:CXDM4_13^EK)%17J(?;:UN.:=UW;W7W6%E:_3P- MNC<4,.VHQ/0_"]V_P"N_'M\,`T-.IGR;^>&RI,AO'XN_&O9^?\`E?\`)//X M#,[9R.P^KFD?:767$NK^Z< MJ^WM\(['FSFB]CV?E>.1766X!\2?0P;3;0#]29C3!`"TR":$=.-H;8CPK?6I77=7!_2A45R"2]10JM0>@3^&ORQQWQ&V#TO$_ MFSL?+_&3L'8>UL%USL'LK<]=3YCH+NB/#P?9T%9M+MJABBV_AL_5T\:R5&R MC4LE.SOD9W$8/>=^3Y><]QWSGOD2_3==MN)GFF@C!6[MM1J1);GO9`<"2/4 M#QH`]!WD#GB+D7;.7O;OW$VV39]TMH4@AN)"&LKO0**8KD`(CD9:.325J!4 MDTZ,E\_.I=WYG:FP/E7T1CH\O\@?B=E:[LC9N+HVO_I5ZQR-`M-V_P!,5DM. MDSUM!O[9B/)1J2.,I2T_ATM(S>PO[=;S907FX\H.:2!JF1FG](%_N+LM_O>ROS#>PTYPV21;#=E&3 M(%[;6]^:RH!&S_B.@@!<]`KVPW[;MAWZ/EFPGKR3O\3;CLS'`C+=UY8?T6A< MF1$_""X)+8Z9OCG\D<9\5OA-\K^U)L:^Y-UM\Z_E=L_JO8M,))7F[GOD[:%E\S_J_M\E MQ?AAMX[96FE8G`TH#2N"Q4>?2?E/FV'DKV[YWWIH?&OOZR[E%;0CXI[F6Z9 M((5`R2SD%J9"!F\N@W^/7QORG97<.U/C)N[)IO;!=#;SH/EY_,/WZ&2IH.Z_ MFWV'IW)U[TT]9&!2Y;:?4U&$KZRD`>C,-'0P30Q3,;FG,G-$6U[+>?]2"TKP:V%'9ITYO]P.6.28HOWS>EMPFQ#:PJ9;J M=JT"Q0KW-4XU'2@/%AU5=U;\A.]?B[WA\COEQ\I/A[VEUC\?_ESF>L\[)N7; M&3Q?9^Z.@:#JK9(V#BJSN_8VUHI,]@L;NG&)'D:BHI4J#B9'--)'))^F7-WY M;Y?YLV#ECDWE+G6TN^8]F2=-$BM!'>&XE\9A:RR=CM&U4`8CQ`-8('4+;+S3 MS+R9S'S;SUSGR%>V?^^R6[F2-EN)+);:'P5-Y#'5T61:.S&\(G003PMAW? MAN@_G=\;-V;4Q^Z-M]G=-]Q[5K<NYMH96AS%-3S2+'48_+XRK@>58 MBIZR%)52>CKJ9/(BLI7W#]E/S%[?Y?-]8Q7L-YL%_`4\2)@X!XJRD5TR1.%<`T9'45`(IT#GP M$[HWONS8^\/C[WI7"?Y+_%#/TO5/:U32DN^\$+[OJ_NB@CD)FEP_:>S8XJ MLRM9CD(:H,JV4>SOW%V.PL[^RYDV".GV\1FXMQ_OIZTGMCY:K>6JT_@<>B M#VPYAW&^VV_Y6YDDKS?L]^Z M]U[W[KW6;_,R_\`+3_`$/NR_$OV]5;X6^SKY9-'_S.2E_\2;!_P"]4OOK M:_\`R0V_YY/^L?7%R/\`Y+Z?\]@_ZN=?4Z'T'^L/?)`\3UVEZJH_G9YG:^(_ MEI?(V+<\MIS5+L'#;=IZ@IY:S=$W9.T:S%14."SU5,M#+4G3ZE@@D;@3[ ME[V(@NYO=/E@V@/Z9F9R.`C$$@:OR-0OVD#J$_O$W%E![0%?U%A2,'B9 M#<1%:?,4+?8I/EUJI_R(]G[GW/\`S.FLK@>HDQVQ,!V=NS=]3")?#0[=EZ M]W%M22K>,%5BJ=Q;GH=0W#22K[R\^\%>VEI[7;Y#`W3MBMJXX8<@ M<-G!UGBI^9>1+V:^Y.0 M"I&I#BJDG2PHPJ0#0D$$<\>WGGN)80;?S1MYE2%RT;JQ22,F@;0ZYHP`U: MJU`2J"%1\9?BQT?\0>M8.J.AMFQ;0VH,E49O)-)6UF6S6X<]60T]/59S<&: MR,T]=D\C+34D40+,(X88DCB1(U50DYJYNW_G3=&WCF&^,UYI"K@J("2$15` M"K4D^I))))->EO)_)7+G(>T+LG+.WB"RUEVR6=W(`+N[$LS$`#T``"@``=&& M]AKH5=>]^Z]U[W[KW6D'_P`1JFID^E M3USG^]N[GW'VE"Y#:(J"IH"9[FI`X"M!7UH\.MGC^51_V[K^(W_B(!/\+=6">XXZE+KWOW7NO>_=>Z M][]U[K3\_P"%.'_,TOB?_P"&!V9_[T6U_>:GW5/^21SA_P`],'_').L#?OB? M\EKDC_GEN/\`JY'U]^Z]UAJ/\Q/_P`L9/\`H1O=E^)? MMZJWPM]G7S.ND_C'N7Y+5GRI.S)B;=/1W4>[N]+`P0B9MSXG:?8.TL/NO% M0@!I_OJ3;&YO(4ZQAFGEHA"!>0$=3]]YKM>5H^4?K@!:7][':%R:>&TD,C1 MMZ4,BC5X!M7EUR`Y=Y.O.;Y.=3MY)O=ML9;P(!7Q%BGB251YU$^6^WZW^1%53#:CU8"GRC(.&ZU8OFQ\>J?XJ?)#>O0 M$60.6J^NL+UO0Y[!V>&OW7F.LMG[DW=/1ZU5DQHW+F:I52+BF5+\W]Y;\B M24C^CXCL%_HTZWJOY.7_;M+XI?^&?N?_P!^1O3WS^][?^GI\W_\ MUX_^K$772?V#_P"G0\D_\\\G_5^7JS+W%?4P=>]^Z]U[W[KW7O?NO=>]^Z]U M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U5I_.BV%N# ML+^6U\CL;MJFEK&N6)T0?[9RJ_:>H7^\)MEUNOM'S;#9H6EB2 M8@<2D,TZW)EQSWR7N.QV4JI MN(9)8=1HIDC-0C'R#J66O!203@=<^_9SGJU]N^?-KYAOX6?;"KPS:15ECE%" MZCS,%8KQ8`J,D=?11ZZ['V'VYLO;W8O6>[,'O?8^ZL?%D\!N;;U=%D,7D:2 M8?6.:(ZH:B!P8YH)0D]/,K1RHDBLHYH[GMFX;-?7.V;K9R6]_"Q5T<492/EY M@\014$4()!!ZZM[3NVV;[MUKNVSWT=SMLZADDC(96!^?D1P(-"IJ"`01T'_R M/^.'4ORNZDW%TKW3MT[BV3N-J.I=:I?'YC#Y;&S"HQ>?V_E8E:?%9G'37\< MJ@J\;O%(LD,DD;F/+',^\\G[S;;[L5SX5_%49%596%&1UX,K#B/4`@A@""OF MWE+8^=]CN^7N8;3Q=NEH<'2R,IJKHPRKJ>!\P2I!4D%1=(].;)^/G4VP^ENN M:?(4NR.NE?+FP;=RML>V@`QT?LHZ.NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N MH]724F0IJ@KZ:GK:&MIYJ2LHZN&.II:NDJ8VAJ:IIYE>>GGAJW.F M?Y1WP3Z$[OC[_P"N>I)J'?&.R%7E]K465W/G2;_JVW6@ M-_):_P"WFGQ=_P"UWO[_`-]-OWWT6]\_^G5\V?\`-.'_`+2(>N8'W>_^GP\F M?\U)O^T:;KZ(/OFKUU6Z][]U[H#/E!_V33\A_P#Q!G;7_O`[@]B#E/\`Y6GE MK_I86_\`U>3H-\Y?\JAS7_TK;K_JP_6CS_(6_P"WE_3W_AI=O?\`OLMS>\]_ MO#?].LWO_FM;?]7TZYR?=E_Z>_L/_-"Z_P"T>3K?Y]\Z.NG_`%[W[KW7O?NO M=?_3V/\`^:W\HNOTW'UG\(W?&Y:$8]G#PP8[!TU945;I!A>>?:#E/<3:[KS[#;Q>+:5BLW MG98[=+EE[KJ9W[1%:(==$OR*@+:8Z^]O.>UB[V?VYFN9O"O:37R6ZM)ABCI\=BNT.T,4O\ZTV]58E$BDP&WT:H2G9J:HF5T5P7/O/)G M),LDVQV_]8.<"Q9KVY1OI(I#DM!`W=.X:I$TVT95(-.C./8N>N?HHH>8+G^ MK7)(4MA:NOULT8%%6XN%[;="M`88!JTU1V!`/5BG2G2G1OQSV10]<]([(V= MUQM"@"L,7MV&FIY M_DW/?K^>ZO6_$Y)H/X47"HOHJ`/(=2OR[R[RYRGMT>T\N;=;VE@OX8P!J/\ M3L:L['S9RS'S/2H["V/UCVUM'+["[.VUL_?NS,]3M39?;.ZZ#&9O#UL95E5Y M.O2:)B`MJBF0++"]G1E8`A'MM_NNS7D.X[5=36]]&:J\99&'YBF#YC@1@@ MCI9NNV[/OEC/MF\6<%UM\HHTIK?A5WQN]Y7$T0%SC_CYW1D7K,QL21>13XK-FLQ.IF9I0Q4"4_Z MUX.V-9[Z10;I:1Y8^MY:K19?G)%IDX`#CU$']3^;_`&]8S^VNZK?< MNJ:G:;V7"C^&QNVJT/\`1CFU1<236G55N.S^U^RNR.Q?B;US1[LZ#[0S&^O MY@_"S8':^#EV9OCXU_,C8[R[F[Z0(K+XC,]1=RJE3D<'78N>;!RTM76Q:/N M4CC,NRVUWM>U[9SCN;P[CM6XVW9+D[IM,%RABFV_=8?U+BSSVO:W?=)"\9,)5I!36 M`.@>Z&[MSN$ZT[$^97=FU8-F;3^//R"[^J?CQU7O:H7#8W>WST^1V^,K6U&3 MS\58\5.=M_'C:LL8FEG"R43??5$+)+`Z$ZYAV&WN-TVWDC8KLSWFY;;9B\N( MAJ:+:;)0%2F==Y)6@&&_35@0P/1#RSS%[V/]:\N)CJGFL[1Z,P+8BEN`J>&%`6J]6:_&WX5]`_ M&S)9/?&+DR?9G>.Z`9-\_(3MW/KOCM_=E7-$L57JW+DB1MW$3!=(Q^+CHZ01 MJJLCE=1BKFCGKF+FB**PF"6NP1?V5G;IX5M&!P[%^-A_'(6:M:$5IU,//MY MRQRC--N4)>\YDF_MKZZ?QKJ4D9_4;^S4_P`$85:4!!I7HXCUN-D1XYNADCD M5D='G@9'1@59'5FLK;$'@CV"@DH((1@1\CT/C)$0074@_,=5I]C_`'#[6W MEE>[?@UVC'\1^Z,G.^0W)@,)3Q9?X[]MU)D\\M-V?TXF'"PU=<08QE\.M'7 MTOE>8+-;^Y2VSW&GN[&'8>?]I.\[$@HCN=-Y;CA6"YH6(''PY-2-0+51U$. M[>U\%EN$_,7MOO(V+F%SJD1`&L;HUJ1<6M0@)X>+%I=:EJ,W5=W>/R[W_P#& M_P"1?3GR3^1_3=;T#W1MCCZ>[UJ-IU-3O'X]?7XZY__$G,%RGZ+S1%HPX5RJBK">9.>]TY2YLV#F[FW8&VOF&!?I;PQ$RV. MXV+M4R6TXX7%J_ZR03!92A>,,QHIV.L/E\7N#$XO/8/(4F6PN;QU%E\1E"> M.IH,<\,MM--;W$92>-BK10J MRFA!'D0001Z]99P3PW4$-S;2J]O(@964U#PJK`CB"""#YCIQ]M=.]>]^Z]U MBF_S,O\`RRD_Z$/NR_$OV]5;X6^SKY9-)_S.2E_\2;#_`.]4OOK:_P#R0V_Y MY/\`K'UQR]QMDX,.U.8ZJ5JF`BH#QZ%"!WP+]M?9BPY\V3]]WG M.4-I^NT?@A%>0::9;5FDM6JC2<4-36@Z,>ZWOMN7MUO_P"X+'D:>]_063QV M=HXCJKA-,4FH+2C'4.ZHH5.LE\FOY@':G\RWLK:^UODUVYM#XV][:RRLN<-]@VCEZ%R51(II(HV^$NR1AY)9$@%B`HJ%":FKMF_REOC'\+>ANDJ[ M/?%#L_`=^9;>\?-?//,._1V_.&TR;=#`#X%J0="@TJXWO+/+LESR1O,6YSW!'CW8(UL14B,H,PM21$W=G4Y8T(`K^9Q_.)W#$ MMSY7JOKOXZ;QW3O&F@Q4:]J=BXO+[?Z4CR&;PT6;I:7;=;0QK6=A5E'1SA:F M"KQL<,\%E>ZHK%"7!Q""1VDJY M((-!4=!KWB]^[KVZO)]DVGE.XFOP%_QF=62TU.@<",KF<@'N`:,`@C42#U4G M\>_Y]'RN@Z[[_;>QH>[N_P#?&Z.N$\:^OL9L.DI,)M3^(T6]Y-^99\3LVBH ML[N/$8B@Q$=)CYB>LJRH#--XQ.3,G,GW>>3VW/EP6&JPY=UVGF@[CIW'FBYF@3;X%A`2+4)O&;3 M$`\BJ%B"H6+L[5+4U=+#X_S8/YH?9OS5Z[Z'[#PM'V+2[LW=28SL'KC/=7X MGKW,;`VX'L_[3[5R+ MN?,.VSM:O#"6AF2=IEFDX)'1G97\1NWLTE:EJT4CI?[:^]_O+O'N'M7+.ZVZ MW:3SA9X'MU@:"+C)+J5$=/"3O_4U!J!:58'HXW\Q[^>7V%\;-[[NZ5Z4^.^Y M,/N;!YC.[97MOO+`YG"[6RM;@ZG^'Y']=;2B6BDW?AHZA@]+DIZ^GF0I)] MM)%(I8$>V/L#MO-%A9;[OO,L3VDB(_T]JZM(H<559I,^&U/B0(6&1K!!H/O= MK[R&Z\H[C?EWR_P#C+V/O[Y`[PAWONW`=Y[AVOB\Q'@<#MYX-O':&RL_3XMJ/;F.Q>.DA MHDC+K=ZOXDJ%JNS-4A M5JTKD`5Z'/W=.>.9>?.3]WW/FB_%S?1;D\:OH1)X4+A:1JJT#.U#2M#0DT M'1"_YH/\[/N#JKOC/?%7X<8O"0;GV=F/:>\>RLK@X=V9BMWW5B&?9^Q-N5 MRS89&P];5I25-364]7)/7K)%%%&L0EFD/VG]B-EW?EZWYOYWED-I.ADB@5S& MHB%:22N-W`%E52H"4)))HL9>\OWB=^V3F:YY)Y!AC%Y;R"6X9!YF-`8H8 MVJG82%9G5B7JJJ`NIG>GPG_"COJC:2=N5N^>K^X##CUS>7Z3J<;UQF=V10G MW51CI,7@-E;-2KR$,=U-+A,_-42$:(0[Z1[8:?[L6\7AV:/;[NRJVE;H-,L= M>`.IY9:`_P`4L(4<6H.E"VWWL]DL1OLFY65_1-;6A6!Y0.)72D,56'\,,Y8\ M%J>G'^6%_,5^<'RKZX^=FWMMJ;^^4&PZ3%[ZZ-VANS$8[9VV<94YV?,8+,; M'GIJ67!5$.%VQD<53&FBR%8)Q/4F.HJP'9U;]U_;/D+E#<_;ZZ3QK;E.X+17 M4D;-[!`KK"0X+.K-J+2BU5,`%WV<]U_=OXWJG;6,P^)V M4F-_@60V$-P[OK\1EXJG$[IW?1UE1+FZ_)02.L,II]!C71=LB?:&SY&LN5[ MA.0-QFN=E>\=F:75K$VB,,I#1QD`$(&GSK4UZQA][+[W!O^;K9_#'+O)L&SC.?\8#UIJ((BJ<$:BMC_P#,R_F[=8_`A:?KK;.#I>U_ MD-F,;%DZ?9'\2:@V[LC%5B:L=F^P,E2K+6Q/D%/DH\73A:NJA'D>2FB>&62, M/:OV8W7W$U;G=7!L^6D;29=-7E8?$DG&.#2-VJ<`.0P$M^\'OMLWMCIVFSM MA?SVT>H>K MV,XL4L\,B[8_OC@-Z[ZSV/IYH6B%8S2T;25\S,K:9>W MS8/NY^WMS^Y][MYKW=T`UJ))I9$X']3PWBB0D9TX:GX:$5A+E_F/[T/N7:_O MS8;F"PV5R?#8QP11O0D?I^DLSJ":LK7&HD&C#NK^:-_-L_EU]C[?VE\X^N M]L=H;5S.N2@R%?AMMX)=U8RDDB^_EV1V7UG24VVFRM&DZ>:"NQ]540!T\T$8 M=6FS]IO9OW,VRYO.0=SEM+Q.(#._AL>'BP3DOI-,%'530Z6-#TEO?>;WR]J M-VM;'W'VJ&]LI,JS)&GB**:C#<6X$>H5%5=&9:C4HJ"=E7X>_,/IOYM]/8SN M'ISSRT3S_PG=6U^0][EV3>X0):HY%J8Y8R2`Z$TQBA!`92"".LO.0N?=@]Q=@AW M_8)R8ZZ9(VH)(9``3'(`3FA!5@2K05/IK2?\WN$/?[_IZG,?^EM_^T>+J?ONW?\`3GN5_P#37/\`VDS=6X>X:ZG3KWOW M7NL-1_F)_P#EC)_T(WNR_$OV]5;X6^SK2S_X3M113_/3Y`03QQS0S?'SL": M&5%DBEBD[=ZO22.2-P4>-T)!!!!!L?><_P!Y8E?;OEQE-&&Y0T/_`%#3]<]O MNIK>YO-L`5.US@@\"/JK?H@'\T;XEY;X(_-+3ZXVQF'Y!2,T<-/M MG=/7^%3(;KS$M-'_`,!L;G,.L69I8U!"P5BQ`ET8>\'O?9N5K"W> M2ZE4V?F9(YFTQK7S9&K&Q]5)X$==`O;/W-V[G#VY@YOW&Y2.:TA87WD(Y($ MU2/3R5TIH\E<+Q!ZI`_E=;2W#_,?_F4]W?S$.S<74G8'5&>,W6V(R:FHI/ M<]91RX7J_;M.68TTDO7.QJ3^(U1B`T9:6DJ+`RDF>_=F\MO;#VMV'VUVJ4?O M&\CI.RX)C!U3N?/]:4Z%K_H8=?+K'+V9L;OW:]W>8_=;>(3^Z[&6MNK9`D( M6\8\JP0C6U.$I1_Q=5,?SH_^WF?RB_[7FPO_`'T^P_QG_`$ZOE/\`YIR_ M]I$O4'?>$_Z?#SG_`,U(?^T:'K93^(&X?F;M;^4+\1\Y\)]E]1[^[`Q^"W?5 M;DVUVM69JE;);:I]Z[_E6EV:F-RV`HG<=1DDB0)75U-"8R0I+$6Q[Z]MMN:2,(]N%.ES%#F74KD(%KE$8U^767G(=U[@67L1R+<^W>WV M-UNB12F2.Y+C5&)IS2+2R9"U!1W44X9ZJ@Q?_"@_P#F#97?..ZWCZC^.E%O M/);KI-D1X3,;2W]AZBDW/69>/`KB\HV2[/IH\7-!E9/#.9S&(&#:RNDVF"7[ MM_MO#M\NZ'>=S:Q6$RZEDA8&,+KU+I@.H%F]TI]RBVD;%M[@ M\XAT-%.I$A;1I;5<#20V#JI3SIUMO_':H^0M7U/MVH^4F.ZOQ7LY^5'YJ?8[1^-&-\[?JJ+8(+ M='N(SX2(&.&,1\)P4U8%6U4()''K&[W;]U_>'VROVN9MFV5^6KBY=+60"9W MKW)1XR$2%,M1=%00#PZ-Y\8OF;\J]M_'+?7RT_F2;;Z4Z,Z7AV7MK=O7='L MF'6FILQMK);CW'3QUVYH:J@BQ6/$T61>IGTSQ1`$@%\U\C\H77 M,^W\G>U]U?[AOAG>.8RE#`NFE2KJB&B$.9'H4"BJD]#SD[W`YVM.4]RYY]W+ M3;MMY>%O'+`(1()VUUH'C:205D!01I42%FHRKU4D?YNO\RC^8#W)DNJ/Y>G5 M^'ZXP='!-7C)5VVWN?<^VZE4M,FY-_[OWK'5;!VO#4NR".EIZ-I!QABFJ MW`)F3_69]KO;G9(MX]R=V>ZN&(&D,\<;/2NB&.DTA'FQ:E.YE0=09_KZ^[O MNCO\VR>U>S1VELH+:BL!9) M:5:A8Y#`TGCDTJN7>3ON_P#N:EU8P7>TRN%#&."2`M2OAL\12QL0"14KJH=)-#2\ M#X_S3^K/F;\?^P^T(-J[AP/9?26V:O/]L].;;I9]X;FEIZ/%5^3IYM8P99"`K,&M MP-LFDA%H&#]C?A9J(/F9_PH/\`DWELUFNOOC]U;+\9Z>@F%/59OLG"P9_N M(\:2Q--M[.T!VKM!ZFGE5C#)29240R5`O?WD'R/]V[E6&"#F'0^))0^8:,>17K&CW`^]-SC/<7&U'76PL?\7,%4BGZ_ZFZ]G^0W?5-U6NZTR':M9M+%5V]S34 M]5B,CLK9&U\;FIB$-/2^2IFCDDB:G$:M[8/8'D:RW/<9.;;@:KF\F%G:&X M\/3;B1A%4AEEED9:'#44$`ZFJ1OF3[R'N%?[5MD7)EL=%K8P&^O1;>+JN3$I MFH"K0PQJ^H96K$$J52@)NOB)_.3^0>'^"W>GR@^7.Q\9N^@V+NW;'7O16[,- MCZ?8U3W7V+NFRTN2V=5T=%2G"1TFSH M6Y_<#E_E/DR_>&2XADFNXV)E%K"A73"3JK256-V)U:3J"MT.N1/?\`YI@] MMN9>MN2>VGC@LY440F[GD#:HB`-%(@H=Y$4#3J72SK3HLWQP^7'\[C^9 M=N/?&X_CIV5UQU'L79>0IZ;)S-MO9V!V+B,CDXYJS';;I,CG]G]C;XW!DQ0Q M>23FHCB0HTS1>6(,N9^3?8;VLM;"UYFVNZO=PG4E1KE>5E6@9R$DAB1:X'` MDU"UH:`_E+GK[Q7N_=[E=\I[O:6&VV[`,?#B2%6:I6,,\4\SM3)^(`4+$5%6 MCY1_S"OYS?PHW/U3LGY.U&T\7AJ7>>+WG9&T=D[3K!]O+S9-NYQ:!+=;A9/J(H8BMW&A&N(R/ M#I3XE$<4HJ"<$=;B.'RU#GL1BLYBYUJ<9F<=0Y;'5_IJ'(TT5923K_`+3+ M3SP_P!?WA1/#);S36\JTE1BK#TFA'[1UGM;SQW,$%S"U89$#?4,`0?S!Z MYRN5M]_4!$G: MBQ7'D-1X1S'SK1'.5(8A.N>OO3]W3<>7)[SF;D:U>YY<8EY+=:M+;>9T#)D@ M'$$5>,88%07ZJ]^$/\Q+Y&?`_=YRW56XOXOL3+5L%1O3J/<\U56;%W3&A5): ME19/+MS<7VZZ8\G0FH&E5F$\F%I9Y]]M.6?<R\'=[;1N"1%<1@"6/Y5 MX.E>/4<2NEN[J&O;GW6YL]M+_Q]DN_$VQV!EM9"3#)ZFG&.2F!(E&X!M2C2 M=Z7X)?S$>A/GSL6?/=99&3;^_MOTM-)O_J3<533C=^T99BD7WT/B\<6XMJU% M2VBGREOB8E4F2GG)@7G_P"X/MIS%[=[@MONL0DVZ0GP;A`?#DIY'^"0#)C; M/FI9>[KI+[:^ZW+'N=MK7.SRF+V,#N(XO-':\G<>?Q53NM]U;@%4M`U+U?LZG>EKJ$Y']BFKJP5@ MR+&\%(S%++EY[??=QLY=LAWWW!NY(MM0, M/E;,IU[D<;\;7=#T07S"E?9D^WXIJ>J>%>)YH\@"=!C$IT^WI6 M^ZTEV=H,&:Z?&5KTQUX5\76017\0!3SK3IB)?O>O9#>A<8Z_`9;`24XT\(H M"#3\!(?RI7'56/RV_G!?-+Y)]1X_X]=GR8WKG(;:W97/V+E-BT.=V%N?>55A MC]E1;9WGBOXBRXQ<#E8YY:NEIUIH9ZI8O)`C4ZWEODWV5Y&Y7WF7F3:0]U'+ M"/!64I-'$&R7B;3W:UH%8ZB%K1CJZA;GGWY]PN;MBBY5WDI:2PSMX[0J\,DI M3`CE75VZ&U%E72&8+504SM'?,+^87)_+G^/O2N+H.E>U>]MRU?4&V/M=VO#D M:7KS$QX/"X;!?Q/LCL4TF9FBS60K'29J58GGJ->IYHO(C-B9R5[;#W-YDWV: M3?;/;[47LE8ZJ9FULSZ8(:J-(&-50!2@4T(ZS-Y]]U#[3\K,P.`KL#'1Y/%9"AS%7%D-XUE?$JM#(U5DIHY$D;]M;)IE#W<] MG^3.1O;H[AL]M,V[QW4F>21F=P]58%12,#S&E`00,\:Q)[+>]W/7N#[GC;= M[NX5V66TF86\42JB,E&5@YU2EAD$M(003@8I?I\S_EA1?#GIV7M:IZF[1[DJ M9LS!M_&;2ZMV_49BL6NJ,=D\F,EN;(Q15$.UMK4U/BI!/D)(I]$KQHL3LX'O M';D;D^3G;>QLZ;Q:6A"[23N%%`RKIC7!DD)840$5`))`'63ON#SO'R#L#;V M^QWNX.9`BQ6R%SJLVJ1J$1Q@=3D&A(`4D]:PW5G\\[YB_)+YM?'#9^(&S. MI.G]W=V[!V?FNN,!@Z'<=1G=M[IW+C\'D:;S>/>[U#832+.[E`CQH74I&A"@5`J',A(J]8<;+ M]Y'G[F[W$Y2L(/I['89]Q@B>!$$A>.214822R`N6H30QB(`T.G'6RU\Y_F52 M?"?J:G[)EZ>[/[GK\GDJG$XS;W7.%JNCH)Z7&U&4FRF]-Q1TM=!M';L5/3, M#5-3U+L_"1,`[+BUR!R0_/>\-M8WNTL8T4,SS,`2"P4+$E09'J?AJHIQ(Q7+ MWW)Y_C]N]C7=VV&\W"5WJD"$A2%+%I9$11@#XM+&O!3FFN'\9OYV/S&^5' MS^^.FQYZK9O6O36].R:':N7ZMVOMZ@RD.4PF8IZFF=L[N[<--7;EK,O2FTL< MU%+C8!H/VX&I3D[S5[$1RI5E(/9&A"!3P(8.:? MBZQ,Y/\`O$<_VL]O9\OW%V(VMHXU8,C@COE<&0L.(&-:_A\NMLCN M3_F4/:O_`(C??/\`[S&4]X>;'_R6MH_YZHO^KB]9O[__`,D'>_\`GDF_ZMMU M\_/^3M4YB_F,_'>MPN,&;S5$_:59AL(U;#C%S66I>E^Q)\9B&R52KT^.75 MT<`&:A;2IN80S:1EM(J:#)I3KEU M[!O-'[L\J26\/B7"FY)4+K86DY5=1PNHT&HX%:GK8%W_BO^%%W:.'S79>`S M/3G1%-3M75^%Z(VS5];UV[Y.)G:EQ\.6SVW-]XO(5[P(`/O-Q4HD)@_PPM0>9X]91;I!]Z_>8+C=[6X MV_;$%62SC-N9:>2AGCF5FI_'.M3Y#@"P?"3^?=W?M/N&CZ2^?F,Q=7@Y]R-L MK-=E1[8IMC[UZQW+!7-BA]^;=QE-0X2OPF/R49BR`BHJMH`))CY]'A(LY\ M^[QL-YLC[][=2N+@1>L'B&6="-0\%V)8,5RE697PO;75T#?;K[S?,=CO\` M'R[[GPHUL9O!>X\,0S6\@;2?&C4!&16P]$1TRW=33UL\?)N2.;XR_(261)8 MI>B>V)(I8V5XY(WZ_P`^R21NINCJ000;$>\4>5`5YJY;5A0C<+?_J\G68_. M)#YZ#IW>%5@=MRYNL!I,/'F\I%%3-52_MP"36W"GWT#]]HK2?V[O8+^Z,%B M]Y9K)(%+F.,W,8=](RVE:MI&32@ZYK_=XFO+;W-L;C;K,7&X1V-ZT418()9% MM92D9KP^R,/_`,-MY[;R_;.)W-U)U82&JR]!T%L/\`T:9# M=\='$KU8^B?/;9WKCUS_=DL;J'9YK6\NZD M;N;QQ'7AJ.AXF45\U@``S6F>LCMWM_O9;A:3[Y!>6-EI!9;'Z=I:#.D:XYE M9J>37!).`XZ!'^7U_/M[2K.VL#T3\Z'!/0;BST>T7MZBP,.RL]LO=UOWF]ZDWRUY:]R8XS%++X0N@@A>0G M2!<1BB:-7:SJ&,Y8,Z=L__`!_'O#KK.+K_U+;OGIOSXD]9_-'>^U^[_P"6 M]%O+L/=L&(W;1=^;D^4^Y^M]I[UVWG$7;N(R]7N&K-)M[8M+]]CY,0U)55-- M1TTU/XM8C:,OEE[>;=SENO(UA=[#[GF#;82T9M$L(YY(G3O90@J\IHPDUK, MP:M@TPS]S=SY&V?W"W&RYC]I!<;K.%E%[)N4EO%-&_Z:L9#1(1J4Q:6944K MIK0@E2T/Q!VME**DR>+_`)%Y/&Y"F@K;[P.B5205;9Y`01@@@Q`@@\0)_P#V85?^Y0__`%JZ<_UOK?\`]EG;_N=1_P#6[KW^R987_O0W5_\`I>^W M?_LW]^_KQ/\`^S"K_P!RA_\`K5U[_6^M_P#V6=O^YU'_`-;NNC\-,&H+-_(< MJ5502S/\^=NJJ!Z6V1_[H:?N"C[!Q\6&WQLWYD9KLW;O566V;4 MQ;DW#FG=VUJW-[62JZZQ]&P\O;=[,J-^6Z7 M1-%NKW$=LT1$CN98R\=8%'B.BN:4"G+`=&N^=7RD^#':_1VU.X/XE0_,OJ/ M9OR)[.ZAS:;7WUE^MHMA]P9W+4DLFYJO;VU(A-R4G<%0OWE%FI4,M09XKVF MK60@_P!O^4N?]GW^\V5^\S[9! MK>G^CN_=K4^_^GOY-6W^U]J5;BF&X=J_S$=O95>JAC4/C,K2U>];-8/4: MV22CKJ>FJ8;6,8`'L1;OO6_\NW;;=O?O?)9W@SHDV9UJ#^)2(BKJ>(9&93Z] M!C9=AY^HU"/PL#'1AP.JL/3H1_]DRPO_>ANK_\` M2]]N_P#V;^RO^O$__LPJ_P#_V3+"_ M]Z&ZO_TO?;O_`-F_OW]>)_\`V85?^Y0__6KKW^M];_\`LL[?]SJ/_K=U[_9, ML+_WH;J__2]]N_\`V;^_?UXG_P#9A5_[E#_]:NO?ZWUO_P"RSM_W.H_^MW15 M_D)E/AY\70N#[T_E!8O;&5KZ5,N^P:#YT?WZW8^(A#2?WCRNR=EY[<>0QF!I M2@_R[(0T\&H@([,0/8NY;BYVYLK<)H\)\< M>F\=CNJOHO&1;%PT^+Z>K]T9#>5=UQBZZ)J[&[3K=P90+6U%7BJ&ICCDA;T MT3@TR72%3[Q0YPF>?F??)9=X&X2FX8-^2)XGKM+U3Y_-=_EL]1?WH+L7?VV-CX M';WR,Z_VOE]X[,WM@,738S,;M;;E#/E:O8VZVH(8O[Q46X:FDIZ1ZD/-0UK M121NL?FCEFGV?]T=YY0YBVS;KN_DDY9N9ECEB=BRQZR%$L=3V%"06"T#K4$$ MZ2(%][O:/8N=N6-VW.SVV+FRUA:69%"M+X8+&&32!X@<`JI:I1RI!`U!M- M?^7Y\Q=]_"GY)[$[1VSF:^'9U;F\3@>VMJQU$HQ.\>O:ZNC@S=)7T6H4\V2Q M%-.];C)V&NEKHD8'0TB/F][C\D[?SWRON&TW4"F^6-GMY=T;.X86#2ES'7ME@)HX8<"R@EXSQ5P#P)!V_/Y_ M!HZ[^6SO2LC$%5%_I$ZEK:"ITI%\^Y88TJJ:0@Z&EIEU#+8F.0CZ$^\+ON MZZX_=&Q0U!^FN`1]B<#^8_:.L\/O/>'+[1;A(,/J[8J?MD&1]H)_(]5+?\` M"9[J[;F?[C^27;64QE'6[@ZXV1L7:^UJVIBBFFPQ[%R>Z)\Y5X_RS4M;4T. MRTIC,EG%/-+'?1X:8OO3[M=6VR"L80'U`,I:AQ4`\ M0.H.^Z!LUI=;_P`W;Y-"K75I;0QQDBI3QVD+E?0E8@M1G26'`GK;]BVQMN'< M-3NZ';V#BW76XR+"UFYXL301[AJ\-3S_`',&)J3_`-U_]]MUK[+_O1_\`[[)_P!M/\`J_/T9_=$_P"5`W__`6[_P#: M/;]:_P!_-O\`C9VO\5/G9V;ONMILO1[9[7[)SG=?4?85.)VHZV3.YS^]-904 MN3(9(=Q[)W!6-3SP,PF1$AG"^>)FR-]FN:-GYO]OMJV^-D:ZL[5+6XA-C0 MGA@E?-)4%0>!JRUJIZQ>]\^4=\Y)]RMXW1)%L[Z[>[M9Q6AUOXA4-Y20N=) M7B`%:FEE)OX_E_?S]>H>X:';?6'RZ>@Z=[8,5%B8>RPGAZGWO7+&L"UV5J`6 M;KK+U\BAI5J0<1Y&9EJ:=62!<=/<;[NV];))=;MR8&O=GJ6\#C<1#C11_HRC MRT_J4P58U8Y/>UWWGMBW^.TV;GHKM^]T"BXX6TQX58_Z`S>8;]M2'4$+D. ML?B9\=NMN\.R_E#UEL^CP_9G>F&HH-\;CPV8KYL#N.EEJ:3,29>BPJ5DNWZ: MMS]92P5575TT2M62KYF)>25Y(2W7G'F;=-@VKE/=;UGVK;W)B1E`=#0KI+4U MD("556/:.W@`!/VSSV"Q[QN48$TB.Q205#Z@E=`+D!F91W'N M.22=1O\`X4A_]EU]?_\`BLNQO_?B]L^\RONP?]._W+_I:R_]6;?K!?[VW_3R MMK_Z4\/_`%?N>ME[^6ON6@V9__^-N\,KJ&+VI\?VW+DBA`;[#!0YG5FDMZ M0WV]UK\>\6O=UDOO=CFBRA_M9MQT+]KZ5'\SUE][17D6W^S?-_/\`V,&U M^(W^E0.Q_D.M'#KF#<_SZ^>VS(NQ9^2?R!PS;QJQ/\M#@MR[F@DS%) MCY/U04FW]K]/1(ME@@IXT4!5`&?.YM:>W7MY?-MD0$&U[:WA"G%T0Z2?4O) M0L?,L3Q/7.':5O/<[W-V]=UE9KC=]T3Q37(220:POH$CJJ#@`H`P.OI.[?P& M$VI@<+M?;6+HL'MW;F)QV"P.%QL"4N.Q.&Q-)#08S&T--&!'3T=#14Z11HHL MJ`/?+NYN9[RXGN[J5I+F5V=V8U9F8DLQ/F2223Z]=<[6UM[&VM[TA6.TA1 M41%%%5%`554>0```'IU7;_-QZ`P'R"^`_?V+R>,@K-P=;[-RO<6QJ]HT:MQ. MY.N"JW#.U!PO$^9V]35V-E%[-#6-^0")+]FN8[GEOW$Y=FBEVUU.MM/) MDF(05_TKE7'S4=13[Z,_)CUJT_ M\)__`)!9SJGYTX?JK^(3KLSY#;8W!M#-8MI&^Q.Y=KX7;SV?FS#J"?Q"D?$ MUE!$_P!1'DY!R2/>6WWC.6[?>/;^?=_"'UVVRI(K>>B1EBD7[#J5S\T'6%_W M7N:;G9/)U\O$C1I8GI_$-+(#Z2'HWG_``IP_P"9I?$__P`, M#LS_`-Z+:_L&?=4_Y)'.'_/3!_QR3H=_?$_Y+7)'_/+X0]_O\`IZG,?^EM_P#M'BZG[[MW_3GN5_\`37/_`&DS M=&QS?\P+X/;;S66V[GOEET!B1[!UO[<<_74$-S;\G;D]O(H96$$A#PJ"#IR"#4?+H<7/N MC[87QV_P#1J[1_ M^N?M[_6Q]Q/^FW/_LGD_P"@>F?]=GVQ_P"F]VK_`+8O^@NC2;2WOL[LC9V M+WSU_NC`[TV;N3'25^`W1MC4>:P68HM4T!J<=DZ"6>DJHTGA>-BC'3(C;, M"`$KRPO=KO9;#<;22"^B:CQR5=3@T92`1@@_8:]#2QW&PW>PAW+:[RXV^9 M-221L'1QD55E)!R",>8(X]:;W_"=7_LOGOS_`,0!O[_W[W5WO-O[S'_3NN7? M^EE#_P!HUQU@']U'_IYW,_\`TJYO^TJWZNW_`)WWPR7Y3_$3+[UVMBS6=L_' M9,KV/M'[:'R5^9VFE)$>QMIQA5>:;[W!4"9&GB0&26MQD,2_YUKP/["\\'E' MG.&PNY=.S;GI@DJ<+)7]&3TPY$G`61B>`ZR^\9[?CG3D2?<;'5OFTZIXJ M#N>@\>+U-44.H&2\:@<3UI(]4]^=U[(ZW[<^//6V8KQM'Y+_P!R-N[TVO0P M3U5=GJS;FXXLEMVFPHAD$E+7YLG-%4"-6-;23M`X92+9X[QR[L5_NFS\4A(`0.FERU>(4#4_"PU#/7.O9.9^8MNVC?>5=HN&^AWCP8Y8P"2 MYCDU1A<&8G0U/C4E3CKZ%'\NSXH4'PR^)75O2_V].N[HL8-V=GUT#))_$^R M]T14]=N=_N$]-33X=UBQ=+)QJHJ"&_-_?-OW+YPDYXYRW;?-1^B+^'`#^&", MD1X\BV9&'\3MUU.]J>2(O;_D;9>7M(^O">+<$?BN)`#)GS"8C4_P(O6DW_.C M_P"WF?RB_P"UYL+_`-]/L/WG=[&?].KY3_YIR_\`:1+USN^\)_T^'G/_`)J0 M_P#:-#UN(?RGO"CWM_Z>GS?_`,UX_P#JQ%UGO[!_ M].AY)_YYY/\`J_+UK)?S^OBA-T)\NJ3OC:5#+C]D?)"EGW:U31(\$&)[7VZU M'2[XIXY8K&"HS`GHLR'+!Y:JMJ2O$9ME5]W3G`2!K_:R(Z'):W>I MB/S"T:GDJK7CUAY]Y_DAN6.>H^9K&,IMV[J9:C`6YCH)A4<"]4EKQ+.].'6 MU-_++^5^-GCC(L&?QH/3P9:LH'^D.J,GU0]9J^SW.PY]Y M`V/>Y)`VYG@W/J)X@%APN!A8ZF@R&3F3@EA[FWVZI[;>S7,_/T MHT;QN9\VKQH"T41'_-PRRGU1%/4!>Y]?=3WSY2]N(3KV/:1XUW3A4A99@?^ M;8BA'H\C#H%/^%W?F6;>707Q;PU8:/:^&VM5=Q[IQE(YCILAF M.O\`I.@[][SF><[ARQR9;R:;..$W4BC@SLS115']!4D(']/Y=6,_\)[>E,'U M[\$J;M&+'Q)NGO??V[-PY?M$HK)\!LO+UVQ=M8GS6U-C\?48;(542WLLM?* M?[7N,OO([[<;E[@MM)D/TFWV\:OD'E42NU/4AD4_)%ZEC[K'+MMM7MJF\B( M?6[G=2NS>92)C#&M?X5.P'J[>O1;/YY/\Q?XT[HZ%WS\+^M\S2]O]O[MW#L MZ'+U.TEBS&V.N9]L[NQ>?GBJ=PT[24F2WC528G[!"@-1)3_`',OW+PNJQ2B MCV"]LN:;3F';^>=T@-ELL,-D%$.5C&K7K>@.D:01D!'[R'NQRA> M\L[E[>[1<+?[]/+$&,7?'`8Y5<@N,-=.@(FHKJ.LJ0%+5_(2_EU_(7H3=^Z M?E/W5CLCUEB=[=:5&R-F=99A93=F=H5XX8TC,[WWA_'&W!R=9+,O8` M`L2=+/W9/:CFKEB_O>=>88GLX+FS,,5NV)75W1_$E3C&!H`16HYU$D`-577 M_"A%$3^8GFF1$1I>G^KWE9456E<4N7C#R$`&1Q'&JW-SI4#Z`>Y9^[<2?;2" MIP+V?_"O4,?>F`'NM<$#)L+?_`W6US_PZKVGUG_`"]OC#@<#B,=!!N[J?;W M8.YVCI(;YW<78^.CW1GWLT8;(3.;K[D\U MW%Q,Q:&\>&/)[$A/AH%]!VZL?B)/$GK-SV6V6QV?VLY.M;:!`L]BD\F!WR3K MXCEOXCW:7)14\$?DJ6II(XT>:5%84^Q?.UKR_[@_5\ MPWI\_MVMVGD8G2[-&R,[L2=),80L31=0)(4'H'_`'A>0;OF7VT^BY9L1XVW M7WV\2A=:LBR+&B@#4!(9`H%6TD`%F`ZU=OY8O\T'?'\NW=VYL+D=JMV!T MKV!D:"KWYLE)TQFY,/FL9&]#%NG9]?4K]M#F8J%_#54=4!3UT<4:-)`\:3+E ME[K>T^W^Y=E:SQ7GTV^VRD0RTU(RMGPY`,E:Y5ERA)-&!G#/V<]Y=R]J;^\ MMY;+ZKEVZ=3-#73(CKV^)$QP'`PR-VN``2I`8;@^WE\"_YPGQ_K-K1Y'&=J M;+CK\1G,ULZJJZW:79W7&XZ)G-!65E#2U5-N#;=>JRS4PK:26AK8))HHYIX MG<'"J:Q]P_97F-+LQ/:7VED60`203(>(!(..#:6`=2%)52!UGI#N'ME[]P.U<#2_8X+; M6&Q>W\+1>6:?[/$X:A@QV.I?/422U$WV]'3(FMV9VM=B3<^XVNKF:\N;B[N' MU7$KL['`JS$LQH,"I)X8ZE2TM8+&UMKU33;0QJB"I-%0!5%34F@`%2:]//M MCI1U[W[KW7O?NO=4+_S)OY(O4_RDI=P]M?'>DP?4'R$:&IR57C6!,9UQVG7 MJ'F>'<..I(_!MC<^0>X7+TD8CFE:]9#6-1%D-[7>_.\+R$+P5-'D,?.:? M,;;W%C2_VV8P&7IPT-3`QDI:VDDNK,C(_O-F_L.7.?>6VMK@1WFP7T(96!J" M"JZ-Q5U.5.&5AFA!'6`VW;CS1[<\U+=6QEL>8]OGLK"A#:-'(O!T889YNY]I8GJN?'T=6XJ-G[SW5N)-C=EX MFEJSHJ@<304^7-#4629X3!.-)86PCY+]MFVOWRM>4MT'BVMC,UP"1B2-/%@ M8CAW$QZQD`ZES3K/WGOW43=_N^WG.>TGP;S<(%MBH.8I9)/!N%!X]JB70V"1 MI;%>J/^$^?16"[9^'@JXEGIDWK793$[4VS6-$ZM M&U1BHLU65M,Q]4552Q2J0R`^\@?O(+;+1YU!%1XQ98XS3U76SKZ,JD9'6]K[Y]] M=NOG)_S=,1CL)_,A^65%BZ6.DIINQJ7+R11%1LAG]I[;SV7J2%`'DKV')TDKEG%J5J?1)'11^2J`/D.N3?OK!%;^[?/$<! M4-V&H/XGBC=C^;,2?F>MXCY<113?RX_D+'-%'-&WP_[#+1RHLB$KU+DG4E'# M2KJ".."`1S[P(Y,)7W.Y:D@_OJ'_M(7KHYSRH;VFYI#`$?N&?C_P`\S=:B M/_"??_MXUM3_`,17VG_[I:?WF;]X_P#Z=E>?\]EO_P`>/6"GW7/^GL67_/%< M_P#'!UOI>^>?73/KYO?QICCB_FA]-Q11I%%%\V=KQQQ1(L<<<:=RTZI''&@" M(B`````!8>^GO-1)]IM\)-2=AD_[1CUR3Y0`7WEV!5`"CF/`_YZQU]'NM5 M7HZM7571J:=61U#RF)PRLK`JRL#8@\$>^8L>'0CC4==:9`#'(",:3_@Z^^FWND2?:SFPGC^[6_P# MKDW[0@#W>Y,`&/WHO_'CU]##N3_F4/:O_B-]\_\`O,93WS:V/_DM;1_SU1?] M7%ZZH;__`,D'>_\`GDF_ZMMUH#?R6O\`MYI\7?\`M=[^_P#?3;]]]%O?/_IU M?-G_`#3A_P"TB'KF!]WO_I\/)G_-2;_M&FZ^B#[YJ]=5NM!+^?9UCA^N?YBN M_,AA***@I^T=C;"[.K>!/'"V8R5#6;7S-:B`!?+D\GM6JF8?KJ)I&/)/OH MI]WC=9]S]L]NCG;V>WVGW7W.6WC"K>V MT-P0.&M@8W/^V:(L?5B3UL^?%+LW+=O?R9,#O3/5)]]^[];;A=2%KC]PW,;$\28(YH:GU)$8)/F>M7?^0M_ MV\OZ>_\`#2[>_P#?9;F]Y9?>&_Z=9O?_`#6MO^KZ=8:?=E_Z>_L/_-"Z_P"T M>3K?Y]\Z.NG_`%\]/^=CUAA^KOYCW?-+@6.BQF]GVEV86&-8HTRN]=K8K) M;EG0+8$U^Z5K:EC^7F/OI+[$;M-NWMAR\]PY:6`205.>V1E0?E'I7[!URO^ M\1LT&S>[7,R6J!8;@Q7%!_%-&K2'_;2:V/S/6T'_`+-CO?\`X8Y_V9K^(S?Z M1/\`97?X+_'?W/NO[W_>_P"B/^\.O5Y?O/XO_EGDU:O)ZK_GWB=_4ZP_U_?Z MJ^$/W9^]M6CR\.GU&C[-/;3TQUF5_7CO[FT:_/Q:_2Z_6NKN MKZYZ_]7;H_F']%Y;>_7V`[WZ\VCC-[]L_'&7,[II]@Y7'4N4Q7=O3V8HHZ7N MSH+<>+K:MI,QB^P-HTIFH(98)C'GW]>#9MS M"QF96M:WFMK=HP(M#(:.016)Y`:C'44^ZO+<^X[7:\S;58)<[YM)>00LH M9;NU<4N[12"&6>(50%329(RM#GHL_6_Q\[`V%U_M+Y?RG^VZ.HZ;[)PE!O MZ/X?=S93)YKI+<%'F[9#)4W6^X:BJJMS=';RBE,M-+1)-+C(\BC15"0QP^," MG=.9-MW'1K/\`NN[9GM'#]S"WVN[;/8_O[9KJ+=^5#6EW;58/2>/XX&%>X.-(.-5<=#3E M;W5V;>]P_JYOMI-LO.2TU6=W16<^MO+B.X0T[3&=1&=%,]+#Y)?.[I#XX9G' M=>5$NX.V>^]RA(]F?'?I[%MO;MG<-34QL]'+5X2@?P;3PDFG4^0RLM+`(0SQ M^4J5]H>5_;[?N9X)=R41V?+L7]K>7+>%;H!QHYS(_HD88UH#2M>E_-WN7RYR ME<1;4[2WW,\W]E8VJ^-F]X34+5FT\=0RY'(R?)3O7%S4F0SE)1T-.\E9BL"]) MC/&H9I@Z,"+X>8>5N4)X=M]N=L.ZBMIT74F_/GY%7]&?$[9VV\+#@H_BS_+7VA7K6]J]Z28JDBA_@ MN]>[8H7R1J@FJKZRMH?%5.\.CW)ESFVM->[=RX1=[A([%_K][D%+> MTU&NJU)":1VHJR50!J]11:PR;HMLG+5BMCN?-`:SVV-`G[NV")JW-YI`&B M6[`,FINYV>/2YTZ"GI7IW8?1>R.P\KFL?4TGPO[]^2GR(^#_P`DZ.&W.X,Q1?%3Y!4D@#18O;&SE4,55Y1RB4FJCF/DE"6-]]WO<>8+_;88)0W/ M.W;79;K9$C_<@/;=PLS_$LJ#Q%CR6[UP]$G+VP;9RUMVZSW$17V]W3=[[: M+\`T%L8[IAMM\/)6A<^&TAH%_3;+4Z/1\=?C34=JR]BTF![&S?Q6_F8?%O/T MO6WK>/:W9NU.V=J!R>HGC@R7\4CJF,PT M1Q^P!S-S2NSC;'N-LCW?VKW:,SVUO,3XEFU=-Q;V]P/U()+>2JA02GAE!IR3 MU)/G#;VV[):[M)LOO!LLHM[JYMP/#ODIJMKJZMC^G<1W,5'+$+)X@?NP!T M:G`_/;L;XZ9[&]:_S'NM:+J"2NK(L1M;Y4]M\MX=I9:I)K#"2HJ!$%U-2,@1AB1D"G1"X^R/F_P#.JT'2 MV"SOP:^,>09ED[L[&PU+4_)WLK#%UM/U=UE6>;&=78;,4;'PY?,O+7B-XZBE MB#`H)#.U\A>W_=OMQ'O_`#6O_$6%B+&!O2><4:=E/&.B5!5S3/49#=_<;W* M[>7K:7EODY_^)DAD`]B/-1%#960[+FXAA6BQM+ M_N/$]/$ZV#L.@OM?(O+E[STG>PVC/L&S/'=;K=2L99[^_/?:VT\[5:18//6377O?NO=>]^Z]UBF_S,O_`"RD_P"A#[VOQ+]O56^% MOLZ^632?\SEI1^?])L/_`+U2^^MS_P#)#;_GD_ZQ]<7(_P#DOI_SV#_JYU]3 MH?0?ZP]\D#Q/7:7I"=I[MP6P>LNQ-\[GJ8/;>SMC[KW/GJJI95@@Q&"P5=D M\C)6(&A:2F?C\_3V8[19W&X[KMFWVBEKJ>XCC0#B6=PJ_S/19O5];;7L^Z[ ME>.%M+>VDD,I4+R3Y3< M&4@QV,H>-0"[RU=6D:`?4D#WUIN;B';[XN[F2D$$3.['R5%+,3^0)/7&"U MM9MRO[:RM8ZW%Q,J(H\V=@J@?:2`.MZ3^>SBWPG\KS<6%DE$\F(W9TIBWF!8 MB9Z#<&/I&E!;U$2-%?GGGW@!]WV43^[%M.!0/#=-3[4)ZZ2_>4A-M[,W=N6J M8Y[1:^NEU%?Y=5Z_\)@_\_\`-#_ECT%_T/W#[DG[UWP\C?;=_P#:MU%GW-_B M]P?LLO\`M:ZVRO>'?6<'6M!_PIF_[)[^-O\`XF7<'_O$5GO?[J__RJ^PS.'JFR&UMWX.28KY::>GKJ5GDJ& M(,$[1N_,G)FZ6NZ;9/<6.Y!0RFA76C9%584DC>G!@R-\Z=9#[ULOW/6T7>T M[M;6VX;67,A]$BX.ET.J.5\5NM:8KUIV?S-_Y(F\?B5@=P][_'[,Y3LW MH+$M+D-U8+,+"_875N-EJ$1ZNEHXH:7=^TJ,RA9:^&GJJ)+-40-$LE4,V/ M:KWYLNYC@2TYB?$;K7P;AJV4GB:`"6(5RX"L@RRE07Z,Y_P`)YOG7V+/V+6_"3L#- MUVY=B9#:>!Y;74:F%H^YXE)SX;)J<+P1E.D#6>BV_\`"D/_`++KZ_\` M_%9=C?\`OQ>V?8G^[!_T[_V_Z>5M?_2GA_ZOW/6QE\%- MJUN^_P"4-U#LC&`MDMY?%/H(!:MW#@=RXBD`)N`3/6+R>/>,WN#>1[? M[S[U?R_V4&[I(?L1T8_R'66'MK92;G[$[#MT/]K<;))&OVNDBC^9ZTK/Y<6Y MJ'K;Y_\`Q4S.ZB<528KO79^$RS5NJF.,GS.5_NPSUHD`:`4-9D@90P&D(;V] MYT^YUK)NGMSS?!:=[OM\C+3.H*OB8]:A<=<]/:6\CVCW0Y)N+WL1-RB1JXTE MV\//I0MG[.OI2>^7/777HI7STWKB^O/A3\J]V9B6**CH.@^T./S:=$^2SNT MLI@,+0@/Z&DR&9RD$"`_J>0#\^QE[>6,NY<]\H6<()=MQ@./)4D5V/YI)^S MH#>YNXP[5[><[7UPP$:[9<#/FSQ,B#_;.R@?,]:/W\E79&7WM_,G^.?\+ADD MI]I9#>&]\Y4(I9+$8#8NXSYIB%I'492JI:8$V&NH4`W(!SV]];^&P]KN9O M%8:IECB0>K/F!]BAF^P'KG+]WG;I]Q]W>4_!4E('EF<^BI#)D_:Q5?M8=69 M_P#"G#_F:7Q/_P##`[,_]Z+:_N_NJ?\DCG#_GI@_P".2=3#]\3_`)+7)'_/ M+X0]_O^GJ[=]Y_>[#;[&Q/UJYAA2/5XL@U:%"UII- MTK2IZCK=/ND;!N.Y;AN`YPNX_'G>33X,;:=;%M-=0K2MT%>DE_T#)=/_P#> M4_97_HO]K_\`UZ]K/^"JWK_ID;7_`)S2?]`](?\`@/-A_P"FUO/^<$?_`$'U M?9\5OCM@_B;\<>N/CSMO<&4W7ANM,'E<;2[BS5-24>2RLF6SN9W)6U-124/^ M2TR_?YF58XU+:(E4%F8%CCQS?S-<_/_$`;^_\`?O=7>\P?O,?].ZY=_P"EE#_VC7'6$7W4?^GG!O-Z]MX^51:2KS'+$(+ MBXJ-#1##,M#J\291ID!4-3E2:BF+7+?W:['8?=.7G`WL+\KPS&XM;8!M:3$ MU57J-/A0,2T9#%FH&`H2=A+WC=UE-U\[W^='_V\S^47_:\V%_[Z?8?OI7[& M?].KY3_YIR_]I$O7C[PG_3X><_^:D/_`&C0];B'\G+_`+=I?%+_`,,_<_\` M[\C>GO"CWM_Z>GS?_P`UX_\`JQ%UGO[!_P#3H>2?^>>3_J_+U_FQ_$M?E]\ M+>R]F8C&BO['V)3GM3JPQPK)6R[MV?1UD]1@J0Z#(TF[=N5%=C$0%5-14Q.W M^;'NGL]SC_4OGK:[Z>73MEP?I[CT\.0@!S_S3<Y/HI'GU?WPY''/GM[N^WP M0ZMVMA]3;8R98@24'_-6,O&!PU,I/#K5U_DE_P`P?;OPVW5WYLOM3BDZQWA MUGN+L;#4U54+`B=H]78+(Y>@PU`)1IBR&_MOI48Y0+O45U/0Q`$D>\L_??VW MN>=[/EV^VB'5NL%TD+$"OZ$[JI8_%Z/Z!&D/6&?W=O=.UY`O>9]NWN?3LUQ M9R3H":?XQ;HSB^C3IJC]6=8UZN$_D$]1;FW?A_D9\_^TXVK.Q/DUV-N'&X+ M)U"/Y#MN@S]3G=Z9#'O("5QN=WW5_:",$B,8%`+"WN%/O%;S:V4W+/MSM!T[ M;M5LC.H_C!(@W])(AJKY^>IZ^[%L5Y?PZ&]#5NN\7;JC'_?:N7E9?Z+ MS'33R\$=59?\0=HYC$_-KK[=U5#+_!=W]`;8I\35$,86K-M;OWM2Y:BC<@+ MY:5?:XPI\JQRS!A]HU2/Z0]>C;_'CJCY>?,C^3_\`%?IOX;]K M;8ZXH=O[_P"XMB?(I,GN/+;8RN1Q%3OK-;BPE%'G,'BLIDDPL.-W/]QDL=#X MY^JIA=XUDC8&\R[QR7R1[T\W;WSOL\MU));6TUEI19%5A$J.=#LJZBT=$< MU"%6X&A`ZY5V3GOG_P!AN2M@Y`WN&TCBNKJ&^U2-&S9GD0:T5FT!9-4D8H7 M#)Q`(-J'P"_D[_&_X308G>N6I?N?OV"."HE[/W7BX1C]K5_C_>CZVVO-)64 MFVEC=BJU\KU&5<7M/%&YA$1^XOO7S/SVTUC"YL>722/`C8UD'EX\@H7_`-( M1C^$D:NII]L/83E+V[6#<9T&X)9;_Q#G6'_`%IS7OH1]VW_`=I#_SVS_X5ZYH?>G_Z>M/_ M`,\%O_@?K<"_E\?]D_#_P#\5NZ<_P#>#P?O"SW(_P"G@UO_`$[;D/\`Z5%K_P!64Z-+EMS;;P-7A:#.;@P>&KMR9#^$[=HLMEJ#'5>? MROB>?^&86FKB&;Y#P1L_A@6230I-K#V$H;6ZN$GDM[:22.)=3E5+!%X:F( M!"BNF@Z&D]Y:6LEO%&M+,9:AP M@)[FWVX]]N9.2A;[9N>K<.7%H!&Y_5B7_A,A\@.$;U7R4IQZ@+W1^[QRKSZ; MG=MIT[;S0U29$7]&9O\`AT0\R>,J4?S82<.M.VOHOE3_`"Q?E6:=JC)=6=X= M592">.HHIJS;^Z&/0"21?'/$6CE2>-DCS7CDY1] MUN4-05+O8+Q"$4>-Q@_..:,\",@Y!D$X$2Q\Z^SG.V@N]ES'9.#535)$.1 MZ"6"5>(."A@&!`^B%\7>\:#Y_'?ISOC'8_^$1=H["P.ZJK#B0S+A\O5TJQ M9[#QSMZJB'%9N"HITD-C(D88@7M[YJ5:==5^3.8XN;^5-@YFBB\-;VU20KQT,1WI7S"N&4'S`KT/7L/=";H@? MSJ_F=+_`,OZFZEK.X,!OS.4W;6Y,MA,?+LG%XW(C!8[;L6)EW!GLM_$LMBA M)#0)G8I34YEJ:@,^A?1S(OM_P"V>^>XS[RFRW%O&]G$K'Q69=;/JT(NE6R= M#58T48J<]1A[E>Z_+WMVS?Q-0M5C"`;$`W'L!WEG=;==W-A?0-%>0NR.C"CRFC1Z@CJ1;&^L]SLK7<=ON$FL M9XU>-U-5=&%58'T(->E#[3=NM(C_A2!M/9N"^:77FX,##24VZ-Z]$X#;YC MIA&LM96XK=6Z]NX++UX3U&LGP6+BI`S>HP4,8^@'O//[L-Y?7'(NY6UPS&T@ MW!UBKY!HXW=1\@[%OM<]AT_P"$S>:H?Y$?([;\K1#)97IG!9:B#$"9Z3![VH: M6O$5^2HDS].6`_H#^.`_]ZB"1N6N6+D`^$E\ZGTJ\1(_XX>A+]S^XB3FOFVU M8CQGV]&'K1)@&I_O:UZW+?>$'6?_`%\Z7^<3_P!O_E=_P"'IMW_`-]WLWWT MQ]D_^G6\G_\`-!_^KTO7'W[_P"GO<[_`//1'_U8BZW>OEG_`-NYOD)_XI_V M+_[Z/)^\#.3?^GF\M_\`2ZA_[2%ZZ+\\?].GYI_Z4,__`&BMUJ&_\)^/^WC6 MU/\`Q%?:?^Q_W"T_T_K[S.^\=_T[\_YZ[?_`(\>L$_NN?\`3V;'_GBN?^.# MK?2]\\^NF?7S>OC1+'/_`#0NFYH9$EAF^;&UI8I8V#QR1R=R4[I(C"X9'4@@ MCZ@^^GO-0^T^^PHPV&3_M&/7)/E`AO>78&4U4\Q1T_[QU]'VK_P"`E5_U M#S?]:V]\Q$^-/M'76F3^S?[#U\Y#^6M_V\N^+_\`XL#B_P#W.K_?3?W1_P"G M6;KZ%_U?_$;[Y_\`>8RGOFUL M?_):VC_GJB_ZN+UU0W__`)(.]_\`/)-_U;;K0&_DM?\`;S3XN_\`:[W]_P"^ MFW[[Z+>^?_3J^;/^:H>LMH9!8W5_MZZH@S&]C3OI_3(M)O%B#R-7^ MP]]"ONWV4EK[:03.M!<7L\@^8!6O[8CUS/^]-?QWGNM<01L";6PMXF^1(>: MG[)1UL=?"_8V3Z\_DG;;P.8@FIJ^N^)7<>\6@G5DE2D[`Q&_]\XK4C`,FO$[ MA@:QY%_>,7/.X1;E[[W5Q`P,:[S;1U'K"T,3?\:0]99^WVVS;5]W>TMIU(E; M8[J6A])UGF7_`(RXZUE/Y"W_`&\OZ>_\-+M[_P!]EN7WE5]X;_IUF]_\UK;_ M`OIUA[]V7_I[^P_\T+K_M'DZW^??.CKI_U\_?\`GL;QQV[?YD_%_RLB,IL18=&_N^V4MG[7;&TJD M&>2>0?Z4RLJG\PH(^1KUR[^\I?Q7WN[S`L+`K!%;Q'_3+"C,/R+$'YBGEUL0 M_P"R^;V_Z!_O]#G\.J_[Z?[W_?G^#^/_+O)_>/_`$S_`,+\5K_<_P`._9T_ M75Q]?>-7]9+#_@C?WWXH^A_>WA:O+X/IM7V:L]95_P!5MQ_X%[]P>$W[P_.3+7FR/NYC MVA8[6_'XI;?X;2[/F2M/IYFR21&QH.H9Y?/^M]SW>OU,B@`,JK4CHQGS9^/\`TUWU\?NR+MOK[;^\VVCL7>FZ=H92OIV M@W#M#<>)VWD:_'YO:NY%Z7.;?R,%72QL7I9XQ%T2!T)4AGD/F/?.7N8]K? M9MRD@\:XBCD4&J2(SJ"LB&J.I!.&!IQ%#GH6>XG_+_,W^[Q[[M<5P8+:62 M)F%'BD6-F5XY!1T8$#L\#48Z+Y_9Z.ZIV%\.NC^U]L[,QM-VEW7UAM?>_ M:W9.0:ISF_-\[CSM(F2R%3G=V9F>NSE11?>2EX:,3+20?V(U))(D]XM_WC<. M=M_V>ZOF.TV%W)%;P"B11(ATJ$C4!`:<6IJ/F>@K['\M[)MG(/+F]V>WH-ZW M&SCFN;AJO--(XU,7EY\[C10B-&-2F(@J9#%)#-[7>VNV3;/ M97'/?TOB[KXPL]JB(J9K^44\4>6R-KJ>TR%14$=%_NKNT.]W]K[>"\\'9_ M`-]O$P-!#ML)U>"6'PO=NNB@[A$KG25;I4?R[>NL"+N+)!:&62HIKA1E"3W+W. M';DV_P!OMLNO&M-M=GNY02?J=QD_W(E).6$1_1C)R`K9-:]+?:G:9]S?Q< M5'FMD]B?,'YI;5W%CWTK(]!E.TLO#]S1S%7-)D\=/HJ2=1KIZF.5"&0'VM M]PMWOM@YOYWK;)O#O[;9-LD0_-;=30CS4CM8<&4D'!Z0>VFR;=S)R1SWL.[ M0"3;KO?MVCD7^BURPJ#Y,IHRMQ5@",CHC.WM]]E_&O=]/VGO-\CG.]OY=LN- M^/?R]AI>=LA\B_Y?6\ZUWJ/Y$4-$IFJ,[G^KH?%7U#SSQRTM>M7,@?Q^Q M_<[?M?--DVT6(6/E_F4->;<21ILMXB%+BS)X(D^4'`$-&44TKU&]KN6\3F7E0K8[H`#JO\`9)36UO@,EWMQ1VXD%91(PK3K8QGIMD=I[)2.LH]M M[^Z]WWM^EJA39"CQ^XMK;KVSG.&MI)):2LBJL;EL3DZ&=)$#H\,J MM?[1?DH\MMN5O(14$I)&Z$@Y%&5E((Q0@]98,FW;UMP$D<-UM5S$#1@LD^=^:KOV[]OWE MWB02[G#=F[9`L;W/T]QX,7C.@5G"QC2031N+`G/6/7MWR!R?9^YWN5'%LD;0 M[3/9BR1RTB6OU-MX\W@(Y98RTI+`@57@A48ZL@^:7R/E^,O1^4W9MW%#=7;. M\LQB.K>AM@QZ7J]^]S[ZF?%;)P,,!>,S4=-5EZ^O]2:RXI7J6_<+FT\G/'TM/&>4]TYWYG/-G,%SN,4/@[9&J MPVL/E#;1#3#&!Y47N:G%V8^?3G('8Y-Y:M=KFG\?=I&:>[G/Q3WPCT-.O>_=>Z][]U[HA?\QRD^:]3\;LO)\$,IB:#N"CS%-59 M>EJ:7!S[DS&QQC,K#FH]VK734D\+5`#O##D#"H:(-(?MB_(B< MT0CW"B=ME9"%(+A%EU5:41]YCH&!I@$@L-(-(R]V4]PWY1G/MI,B[\L@+`A M#(T.E@ZPF3L$M2I&K)`(4ZB_.W[#ZR[>ZVV\ MWMOC(05#2FIC&9I62H;SQEUE0NKVU`D<^^EFV[KLN]VBS;1N-O=63+2L3J MZT(X=I-,8H>'#KE/NNS[[L%ZT.];9/>!7.:BM>/6W1TG_P MI'^.%3U[M^#OCJSN+`]E8_"4-+N2786)VGNG:N,TD\03;G""4-=%O! M44+ZI%WI4S!`H)(4M1A$ONI]X#>/ MXM!6@WWOVFB>6'"S817,V,Q;L:V.MT5%2M.U.D4H(][/?#;=SVV[Y.Y-NO&A MF&FXN5^`IYQ0GBP;@\@[2M54L&)`^]@_N_[IM6ZV?/'/-IX$\!U6MJU"XD_# M-,!4(4XQQGO#T9PI4RN_GU_._J3.]5]A?!G;^W^Q,GW!C][=0DI,W55U>/;W>;?=]MY_N; MFV396@F5%\2LK,28LJ!1`"&/Y>QW.R;K[;VMK=OORW$#2-X9 M6%54"7#DU[JVWV.:#NY>L';F;V=M. MHW,,;E]J9#=M]'EL3!/!EG@R,>\5:)Z.&JE#4Y3Q$NON3_?KV^W?GRQVYV MZM?$L/'+K)($U+((S56(U7P\ABH[JUP>HD^[G[E;+[=;AS#:\PVEWX6X_3 MB-XHC)I:-I11E!#4;Q<%0Q[:4R.MZ%6#K"]F`87!4V(N+JP#`V_!Y]X`'!I MUTD!J`1UIG?SYOG5U)\ETVA\=NKL!V/4[IZ[?WN-^YO<&TYL#@!D,115&TG MH,"FHDR^3$M>LS^:2EIHO%$K)K$@YP?=Z]O]YY5-[S-NUS:BTW"RB\%4D# MO1B)O0:5Q04#,:DUI3KG]]YGW)V/G`6'FS6MV;W;;^;QG>(HFI08M5.IJ MM4UJ`$5KA;_P`@WYU]3=&;>K_B1V'M[L>EW]W/WS19+86;P^U)LUM:HJ-U M[>VMM#'9VHI:AX!CB(I4J?'!DZ>58I9$>. MGFA&W-GM_MGN]R-RCN27<=KOWT43PRD5#:XE9X7`[BFK(U*,"0""RL`>3?< MG=?9/W!YUVM[2[Y=^OFCGA!HR^'RI/&350^G!#4612%)!"LMI'R\_X4!?% M7?\`\9.TNO\`IK97:N>[%[5Z^W3U_38_>VV<)M_;VUH=Y8NV_DLOGJ^EW-F M#D'QE'D'D@IJ-)UJ9E57DB0LPB7DS[N7-^W_O1R[M>VLD`6:-$2,2H49G8 M2/JTAB0J@ZC0$J,]`+_PGU^!/;&+[7J?F=V9M?+;+V+A]G9S;?4U/N"AJ,7E M=[YG=<46.R>Z,;05<<55_=/%;?\`N8(ZID6MJM?`SK#0(OO'^XFSS;.G( MVU7:3[@\Z/<%"&6)8\K&Q&/$9])UJH7N`+#H,_=;]L=\AWM_<'>+2WVV.W M>.V#@JTSRT5I%4Y\)4U&I1V;M)"MT&W_"E7J[=>.^2O2O<;XJO?8^Z>FJ7K M^GSJ4TCXRGW5L_>&[\Y6X:HJT4Q4]=/B-VT\\,;+?1(`] M.T212RN4)X`E958`\16E=)H)?PP_GCXGJ+XK]`_%_KKXO=E=R?(':..INOL; M@<-E&BVSN2&/+U+XVMQ55C/?8;>N M;N8N;-SYLM;'ER9C,SLI+H=(U!@Q2,&&&\2I%.VO1Q[??>/@V+DKE?DW:N3 M+S<.:($$"HC`1R#4=)4J))"Q4Y7PZ`@]U.@P_FW?RE.X-I]@YKY??&S8&>S. MQNQ)T[`[+ZSVG&IS6TJG,22U1J,>LC8VI:4%$I5 MAD!M[->\>RWFVP3MBN85[4#,V%D"T6CTUK3)?4.B;WS]C M=^L=TN.?.4=KEDVV[/CW%O%W2VD[=TA54R\1:K:DKX;:L!`IZ-U\0_\`A1/U M=0=:X39?S&V=V'C.T=I8VGPF2W[LC"X_<6)WO+BX5I?XOFL-4Y7"Y7;>YZSQ M?Y9#''4TLE3KD5H%<0Q@SG/[M&[2;I/?>V7M'MOM8T_./.N]6HW.-E0ZM, M,"L.VN07D9:J**`%+`!BU1'7NQ[U;I[OK;\C\A;%>':I)59QHU7%PRFJ8 MXRX2)6HYJS$L%+%`M#0^"77VZ^YN[X-OD!V-@4I]ONK'[@[E9['L+ M-_5RUDJK-V^/,>WQ"#32B@E8]5#1F9J5`6?_`&"]GI?;3:[[F#F-5_K1=Q49 M5[_IX!W^$"M=4CL`TFFHJJ(M:$MK\?SH_G%UA\Z^U.HZ[I+;?8<6W>JMI[GP M63RV\MKOMZIRN9S^=IJ6/'8I:NOK(Z&AIL3'ZZD03-)RF)=%VR/]C.0=V] MO]HWF/?KJV-S>31NJQ2:PJHA'$]Q]F]RMZV3EVTNQ M:64$B,TL>@L[N#VK5C0!1EM)J2"G5QG\B#YW]1U?3'47P5K\!V+B>Z,'+VC MDJ2NFVM)4[%R^?-[E[#:J&XZ2IEDP\T.+K'@9VG@B>IB"1RLTT:F$OO!^W MN\IOF]>X$=Q;/L4@@4@24E5M0TT$=U6`/:Q.DU(`4GJ??NT^Y>Q/R_L7MM+ M:W:Q\-N>LVC3;4Q]#!M>"IPTE.(-R[ER%9$:#[BKR M$5XZ6FK*A8`SE!Z`\J>VGM9N7N-)>26NZVMK:6KQB0R$F0AZFJ(!F@!RS**T M%>-(?]U?=_:_:ZQBO-FN[N]NXY#$(E`C!2@I)(Q&FI8857:E33A73M_E@?- MRF^"/R&2H@O%,6$ET"MFO[K\AO[@\J6NQ6&Z0P7<%S'C2$E#H1XRK::D5#D M@@'(I3-1@1[-^XJ>VG.-WS#N6T3W%G]R[4QFX\-MSL?;./W3A\5N[%'";DH/(H6CI\MC?-4QT]2 MA4\QRRPRI9XW>-E8\Z]_V:YY=WGA4]E'1WT6#Y?\` MRKV3\,^DLUWGO_;.^=V[?P^5PV%;#=?8:#,YR:NSM2U+1RS"MKL9CL;C(Y%/ MEJ:B>.-"50:I)(T85\E\H7_/&_0?.=MN]O\`EVXYDW2SN9[6-T31`@=R7-!6I557U9F`&!DD`_/6^\_RW M^5?<7R&Q.QL[M#$]C9W&5>)V]D%>NR-!B\%MO"[7QYR-330+3-7UE+A$GF2+ M5'%)45G50[=)>0>7EY-Y0V3EJ;<(YIK6-@SC"EG=I#I!-:`M05R0D"M.N6 M'N/SW//.V_\U0;;+!!=RJ51LLJI&D:ZB!340@8@8!-`2!7K9?\`Y)W\S78] M;L'X_?`/<7579>-[%P]+O3#8/?.QE)E-B9"AAR&Z-^P5>>8U=+F]NNE!424 MKO\`;5-.9XT8R(LI$>+'OO[5;A'N/,?N+;;O:MMCF)GB9BLH-(X2$P5?(#`: ME-"10TSE_P#=W]X=MDVSE;VPN]DO$W:-9D295#0LH:28%\AX^TE2=++4`U`; M&S3[Q6ZS"Z^?M_-'^#68ZF_F09#IKJS%05&-^2NYMN;UZAP5"8[4<_:^Y:G# MU6W6I:=I'Q]#A]]PU\-.I4F.6%OH#;HW[2\_P`&\>V$>^;O,1+M43Q7+GS% MN@8/4\2T10GU?4.N77O/[;S['[MR\O[+`#%N\TMZ?X^=,[:^/'2'5G2&T8T7`=8[)P6TZ6=8Q&^2J<;1QKE38+M0EPJY9:$E)5'FT9)J/Q(S`=VFD;>]WM6ON?RS'!9.D?,=D MS26SMA6U`!X7/DL@"T;\+JA/;JKJZ?!SYM_(W^3MV[O;J7OGIG>`Z]W?7T]9 MOGJ_.Q';^?QVA"P3F*63'Y:FCATU"&**499\_]FS6&\\O;Y!^\H5(BG3O1D;)AF44=:'(J`\;%NTU(ZPR]N/<7FSV#WW<=C MYFY?G_=4[`S6[C0ZNO:)H'-4:HP:$IH6CC2K=7@[K_X4?\`P^I=M+4]?=5] M^;UWQ6QK%C-GY'`;4VS2-DI;)3T>0S\&Z]Q/$DL[!0U)15SF_"7L/<"6?W8> M=7NBNY;OMT%@I[I%>20Z?,JAC3R_B9!\^LC;W[VO(268?:]EW.XW%A18F2, M:CP#.)95..U'/RZ9_B-N/YY=C=I;Z_F:_.'.=B]%?'#JGKC>V9Z_P#C-MR# M-O61UN5IQE,IE$@EA6"BB0![G.V]O=LVC; M_:KD&WMMPYGO+J)9KYRG8X<4`G^%2S=I6,^''&6#%I">D_(MW[F;MO6Y>\/N M/V\I65I,\&WQB0:XRAJ3;CN8O<'D7Q))`I4+&HZUU_YJWR?V;\U?ESG> MZ>IMM;XQ^R#LK9NT<:V[L(F,S.0FV]25/WN0?'4-7DXJEEJ:UDB5IFD9(]; M!"VAGVO50;0I\+LN;(X/=%)55=%4+DN2&:&GJ5 MI:HQR/IC<0R,,/\`WJ]O=ZY;W_=^:+JXMI-HW'<)6B25D!D+2A7C(!%!4%E MU+4#(U`=9N>PON9L/-/+FR\HV=M=1;UMFV1+)(Z1D1!(BR2`D'4:$VEJ$T M!TD]%_X4E[;SM!TU\6NZ]N5^3Q.6ZQ[KR^'H,OBZF>DJMT:"52'20W!O[&/W7KJWDWOFW8KJ-'AN[!6L`0RQN492#Q!6< MU'`CH#?>XM+F+8.2^8;25TGL]Q959205:6,2P(X,K0#21D'IG^,7_"BSJ6/ M8.$VU\P>O>QMI]K8/$45+F-U[&V[C\WMC>3N,]UR5N5K-L\CDK'Y62I^#4%99%7@&)5J"A! M(J4_)OWK]C&UVUGS[M5W!O<<8#RPQJ\LD@I:2%+R&5V3W-G(6R;?[(\A7/];=\A5WG>>0@G3K(@BA!`:1J(. M"@LQ.-(KU`?N-O\`N?O][C6G]2^7YVC2W2WB#->A7=S-.REDB75(?B1[P-YOY@?FKF??.86BT?5W+R!>)52:(I/F50"?,BO71; MDGEM.4.4N7^64E\0V5JD;-P#.!5V`\@SEB!Y`TZ,![#G0HZH/_X42=-/O_X/ MXCLRAI'FR71O:6W,_5SQQEWAVKO..?9&80V4LD3YW8B1SP`(;GWD1]VG?!M MW/LVU2/2+<+1T`]9(J2K_P`860?GUC']ZSE\[I[^+]?EQ,/@-U)F\+28#(&M:3-0 M]:=B+CZ^@QC2UUWO=SK[9[?#;R[:]_R:SG0DFM`C5[Q;SZ6 M5H8MK5$VS/C'V16[U>D<4N/W/N_;&+VM!7-':- MJC,8J'+Y:KI(93MVO;7P-Z>V[ M\&/]D/5:BIZXJ>L\#[KW"WNYY_P#]<(D#&"MBB<256+R--#]U3G0T; MYRW4W7OOR'<6-CN(220],&:UG7(UQU!(!)4D461&;0V:CGS9P\Z?=V]Q;; M<-PVQGCC9TU9$%Y;OAO#DH0"0`X!JT/R^W#N?(9>K9WTT4&,+U#6#"]Q MCF/NQ\TV\ES+NO,FV6^U16,VJ0X'FRLD84?Q$O0?/K%OO91F/\($=6/IUK>?S>JB2L_F.?)^LEI9Z"6LW+M"LEHO MQBKQ\M7UELBHEHL0R30_=T3R&70[IY$.DD6/O)[V74)[8\J(KAE60`C@: M3RBHK0T/$5%:=8D^^[F3W9YRD9"K--$2IXJ3;PG2:5%1P-"14=;^.>Z]H>V_ MC7E^J\G/]KC^R>D:S8=95B/RFDI]V[%DP,M6L9($C4J5_D`OR5]\ZK?):R6M^)0/4QRZZ?G2G73VYVJ/?>4)]DF;3%>;<82>-!+#H)_+57KY^_6 M^;^1/\I7YL[>W9O?KFKHM[]59O-X[([;SBU>/V[V-L[+T%=M_+R["O MPF>P]>9J#)4R5"0S^)VC9HWB]]&]T@Y:]X^1+FSL-S5K"\C5E=,\,JD.NM M@AD84=&()%0#0@]SJSOG?V+GV[A\E/D:;=(V=69B!Z! M\]AL/MC%SU&7J\69S)3U%:^/HZ>11-4!HD:-L>]O^[GM_+5Y'O7/'.-HO+UN MX=E`,?B!370S2,`H:E"%#LP[5H2",E]R^]!N?-5C)L/M_P`CWCQB'<]N=87;``FB(0L/B`[A44U#(I44ZQ,V=;WD3G_`&R?>[&5I]JW2-IT M3N8F"8&15;X6/:=)KI8T-:&O6[1O#^H#:R":@5,!I+_$CMNDZ$^7'2W?VZMK; MGR6UNO\`M7$[SSV+PE")LU)AXJ^22N3&1UC4='4U]/2U#/'')+"DKH%+H&U# M.[G+9GYBY,WWERSNXEN[FS:)&8T753&JE2`2,D`D`UH>'7.WD;?4Y8YZY>YH MO;9[UO5E=4%7T:N[36@+`&H!(!(I45KUN7?GYT]Z=M_!G'=^?R]NBLQW+ MM_L.7?>R][T^\=J9Z+?6Q]O08[(XJW!A.N<7D(_=/PS^3O5W=AVI6/N/J7=J93)[.S\-9@W(XRIIW![DP51]W2FJQ55D<% MDJJG25X7,$KARC:=)SGYJVQYXY4W;8OK%^EO(=RH0X5@0Z.&C!752145& MBM>N>W)_,-_[?\`..S_ M_"E/XNT>P:C(]>=,=U9[LJ;'R?P_:^ZZ79^W-JT>6:`^/^+[IQFZMP5\N-AJ M2+FFQSRRH+6C)N,0[#[KG-C[BL6Y;Y81[6&S)&9'DU_#&T:#41_$X`/KUFQ MN/WN^3(]K:7:N7]QEWTNP\MCJO;L.]HIZQ:UMC=5T=6J5%?35%+''CXJJ MGUT.(H4%Y7FCB@EFGGCW'Y5]I>58>5^7)XY=\AMQ#!"K!S%04\6X(P"#5RIH M\CG@%)80-[?^UW.'O/SA/S=S1;RP\OSW)FN9V4H)JFO@VP.6!%$#+5(D'Q%@ MJMLK?S7>P?EGTW\8EVO\/>@,7V;M7=.TMX=:]CRXG%Y?/[AZOV97[8@P.%K- MG[!V]/2U>2@&.J:Q#4ANGQIIH?)3LDFI,6_9_;>3M\YK-WSKS&]I>0S1SP: MF5$GE$A=A),X(4Z@ITU4OJ:C`BAR\][MTYYV#DX6?(7Z7EE-!+;SE59WMXF MC"(8H$(+#27&JC+'I6J$&HTG/AI\CMR_![Y5]:]Z2[3K2TD820M5& M:-T:.1;,0IS1J4.9.\?>ZY0CVN1]AV"_EWED.E)ECCB M5J8+NDKLR@YHJ@L,56M153_+V_EI_('^87\AY_DW\FL'N#!])YC?59V;V#NK M=>.J<-7=SYG(Y>7.U.U=DXVJC@J:C`9FMD\59D(E2AHZ#7%3R-.(XUE[W)]T MN7/;;EI>5>5;B.3?DMQ!#'&P86RJN@22L@.HRJ'O9Z%AIJ>H4]K/:'FGW4Y MJ;G'G"VECY=DN3<3R24-V[,7,<FA.<.XHBI55):@&\S]G1_9_P_[2F^P^ MV^S^Q\$7V?V?B\'VGVVGP_;>'T>/3IT\6M[P"UOK\36?$K6MND M/AQ^'X6@>%2E"E4I3A2F<*=?_U]_CW[KW15?F3\=IODITEE=I[=RXVIVO MM#+8CL_HC?Z!5J]@]S[%G;+;'W!#,4E,=%45JM09`:7\F-KA-))'L7\DH'>G"CJIKT"N?^5&YNY=GL;2?P-[@=;BS MF\X;N$ZH7!]">Q^-8W84Z"_K;Y&0_)WX-=D;_P`AB/[J=AX7K;MOK[NGK^8E M:_KGN79&V,QAM_[/K87=YH4I,M$:BC+DO+CZFGE/Z_9MNG++FR?C3_2Z![P["J6AVQU]\8]D9B>DA=%K\YD MVP]+1X';&(5P5ES>Y\Y4T]!1H19JBH2]EN0;\XQG_,>ZO2SM=FA<@?$[:`$C7U>1RJ/X MF'ET0/K[I/?W??8.-^-79^N7M#Y%9O;7S3_F@9>D>5/[H=9P5<4-YSO.[21[MS"PK^E;@UL-I!\@0%#) M4,$1V!MUL>DX[#8XLQHL5B<51$LQ,%#CL;CJ&"Y))\5-1T5'31?[3''&OX` M]XQ?JSR_B>9V^99F)_:23^9/66GZ5O%4Z4@1?D%50/R```^P#JK?^4KN_:6Z M.H?D0FV=T;=W$\'S8^4V5F7!9K&Y9HL7N+LW)Y/;^2D6@J9RF/SN-85%',;1 MU,!UQEEY]RS[QV5Y:;SRR;JTEB!V&P4:U9>Y(%5UR!E&PPXJ<&AZACV-O[&] MV'FH6=[%1S%N+'0ZM19+AF1NTGM=>Y#P89%1U+_`)B'75=U_7[^=>Q]K_W MJR?1V%S.Q_DAL.GHXZP]R?#K>;^/M+;%?0R?LY6LZ]$K;CQL+.UY_2T\'<'F-IND-&#<811GCX5N5&L>0<,"2QZ2>U M6[1['?7GMQ)>>-ML<"WNT3DU%QMDQJJ!C\3VK-X9\S&4(4.EO\`$C_LO[^: ME_X>?Q_^![@]H.MC`P5]%B/%_=K! M52&6GDCCJ9XBDH;VKW\?U#Y(M.44[>9MX6.ZOS^**W'=:VA\P6_MY5-""54U M%.D?+9_UQ>?KWG63NY4V-I+3;A^&:Y/;>7@\F"T^GA854@.PHU>K7O]^Z]U[W[KW3/F]O8#,HLM0R`BQUT ME?!40/#QU"CCC\@^RF_W?=MT(;<]TN+EAYRR/)_Q]CT=; M=LFS;0"NT[1:VJGB(HDC_P".O2]]EW1GU$GQ]!5.)FBIB0$$D]-#X0$ MD&D1FT@L3;Z<^[K)(@HLC`?(GIMHHG-7C4GY@'K&FQ<;K)'C:".1&#HZ4= M.CHZFZLK+&&5E(N".1[V9I2"#U/M/6A!"""(5!'R'4_VWT[U!EQF-GD:6;' MT,TKD%Y):2"21R`%!9WC+,0H`Y/T'MP2RJ`%D8#[3TVT,+$LT2EOF!UW#C<= M3R++!044$JWTRPTL$W-I-S/N#VQ%"C7$Q M4CT(+T(^713#R3R;;W(O(.4ML2[!J'6UA#`^H8)4'Y\>A[``````````L`!P M``.``/8=Z$_#I.;LV;M#?N$JMM;YVKMO>>WTHU9M_=>#QFXL)5F(ZHS4XK+ MTM90SF-C=2T9L?I[56=]>[=.EUM]W+!=+P>-V1A]C01^WI)?6%AN=N]GN5E M#<6C<4E19$-/56!4_F.D=U_T3TCU-/4575O3_5_7%75H8JJKV+L+:VUNIB8 MW,514X+%4,\\9/\`99B/\/:W8;VWA'X8YY47] MBL!_+H/;ARCRKN\IGW7EJPN9SQ:6WB=C_MF0G^?2OV/U=UGUC22X_K;KO8W7 MU#/I\]'LG:6`VK2SZ0H4S08@H(I2`HY8$\>T5_NVZ[JXDW3<[BYD'`RR/(1 M]A&%V2X;26C125N`;?2X]Z:21Q1W)'S)/5EBC0U2-0?D`.I?NG5^O>_=> MZP3TU-5((ZJG@J45M:I/%',BN`5#!9%8!@K$7^MC[LKLAJC$'Y8ZJR(XHZ`C MYBO47^#XC_G5X[_SAIO^O7N_CS?[^;]IZI]/!_OE/V#_`#=.```````%@!P` M!]`!^`/;73O7?OW7NN$D<.15='4_561@593_`$/O8)4@@T/6 MB`P(85!Z@_P?$?\`.KQW_G#3?]>O;GCS?[^;]IZ;^G@_WRG[!_FZS04%#2N9 M:BI:0J4+P4\,+E"0Q0M&BL5+#;Z7'NK22..Y(^9)ZLL4:&J1J#\@!T'W MJ]^=Q]DY9,+LCKO;F0W+N"N;2TQIJ/]B@H(6=/N\MEJUXJ2CIU. MNHJIXXU]3CV9;'LVX+,0!D]:KW\IFAWK_,4_F5]T?/[MRA=\ M'U3$]7LW$S:ZG%;>W%N>FKMM=:[2QK2Z89H-C;$HZZ=W10YR(@JG`DF+'+CW MBDL?;/VMV+VYV:3_`!B\-)6&&=(R'GD;S!EE@`XT:D&%ZPL]CH]Q]U_=[F' MW0WV.MM9"L2GI)(#';Q+7!$,(=B1G7I5U_WEF(_ET6[=RCRKM$PN-JY:L+:X'!XK>-O\`>E0'^?0TD`@@ MBX/!!^A']#[(NA#TW?P?$?\`.KQW_G#3?]>O;OCS?[^;]IZ:^G@_WRG[!_FZ MDT]'24FO[6EIZ;R:=?V\$4.O3?3K\:KJTZC:_P!+^Z,[O36Y/VFO5EC1Z$` MKZ"G2>WAL;9786(&W]_;0VQO?`K74.3&$W=@<5N/$C)8R<5..KQCLQ2UE']Y M0U"AX9=&N-N5(/M39;A?[;-]3MU[+;W&DKJC=D;2PHPU0:$8(K0]);_`&W; MMU@^EW.PAN;;4&T2HLBZE-5;2X(JIR#2H\NDIOWHOI/M1X)>S>G^K^PYJ:-8 M::?>^P=J[JGIH4TZ(J:?.8JNFIXUT"RHP%A[6;=S!OVT!AM6]7=LI-2(II(P M3\PC"OY](MSY:Y=WHJ=XV&RNV44!FACD('H"ZDC\NG_8_6W7?6.+?"=;;"V9 MU_AI'623$[)VOA-JXV25%K++18.AH::255-M36_P`?:>_W3<]UE$^Z;C/< MSC\4LC2-^UR3TIVW:-JV>$VVT;9;VMN?PPQI&O[$`'2U]H.C'KWOW7NDUO+9 MFTNP]K9W9&^]MX3>&S]SXZ?$;BVSN/&TF7P>:QE2NF>BR.-KHIJ6J@>P-F4V M8`BQ`/M58WUYMMW;W^WW4D%[$P9)$8JZL.!5A0@](]PV^QW6RN=NW.TCGL)D MR1R&1U/$,IJ"/MZ;,/UEUS@-C8SK'"[#VAC.N,-C(<+BMB4FW,3%M&@Q,` M(BQ]/M\4G\+2E7424\5F9B3(6/F7KJK\Z M],P;/M-KML.S6^V0)M,:!%A$:B)5'X0E--/E3H1\._B2N0&5'Q?^/0R0?R" MM'3/70J!):WD$@VY?R6_M?6_/U]G']=>%Z?4S4_P"/]$O]0N1A M+XW]3=J\7U^D@K_U;Z'W$X?$X''TV)P6+QV%Q5%&(J/&8FBIL=CZ2(?2.FHJ M.&F@C']%4#V'9IIKB1IKB5I)FXLQ+$_:34GH3P6\%K$D%M"D<"B@50%4#Y` M4`_+IQ]M=.])[=&T=J;XP]1M[>FV-O;OP%65-5@]T87&Y_#U)2^DU&,RU-5T M4Q74;:D-K^U-I>WEA.MS8WDM[8V.XP-:[A9Q3VK<4D M174_:K`@_LZ0&P_CUT)U;DI,SUGTEU+U[F)5D23+;ZZVCM?/',H66-LAA< M1159BD46Z])'X]F.X/74_:O^29MW_-"/\`XX.I6YMG;0WI1+C=X[5VWNS'(Q= M#HE=K:F6ERE+50S:1+^&1%4WO>2'$ MTE)&YO\`U!][N]PO[]@]]>S3./.1V<_M8GJMGMNW;(P(P)(0E/&INQ^@_/O7B2!BX5!3]G6#^#XC_G5X[_`,X:;_KU[MX\W^_F_:>J_3P?[Y3]@_S= M3HXXX8UBAC2)`%2.-%2-%'T544!5`_H/;9)8DDU/3@`4!5``'2%WCU7UAV( MBQ]@]<;"WU&H`5-X[/V]N=%`&D!5S>.KE`"BW^M[,+'=]VVPUVW=+BW/_"I' MC_XZPZ+;_9=FW44W3:;6Y'_#8DD_X^IZ#C"?$GXK;:R4>8V]\:^A,)EH9%F@ MR>ZAV!05\$R/Y$EIZNFV_'/!(LG(9&!!]F<_.7-UU$8+GFG<9(2%6N9B#] MH+T/13;\C;RZBZG[&(/876'7F M^R``#O+96V]T$`%`'\;QM=8!18?X>SQWK>-L_Y)N[7-O\`\TI7C_XZPZM MPV+8]V_YNS6ES_S5ACD_P"/J>D)MWXH_%W:&2BS&U?CAT3MS+P2)-!E,)U+ ML+&9&GE0L4DIZVCP,53`ZEC8HRGV8W/.'-E[$8+OF?<)82,JUQ,RG[07(/Y] M%EIR1R983+<676V13@U#);0JP/R(0$?ET/JJ%`50%50%55``4`6``'``'L. M<QJ5T'N<.3)4 MYSV';]BG->8]AN4N;0_BELC*K75O7S,)_P`8C&3I\15``/6/W/<,G(G,>Y9N;8[)UCYKYFW&Y@AD/_$3;(W/UEVQKV^)I9%)H=", M5:IIU$^S.S?A'M&NVOOJDSWR1_F1?)W/U/=7L^L.I\!)2XBGGRE5%34]/!-4TT4B2,ON.=[V"^Y\O8[O;WCVOVOVF,6 MMM=71\.'PD)U2**!IY[A]4A$:EB2JL017J3]@YDV_P!NK"2RW))=W]V]YE-W M=6EH/%G\:0#3&Y!V]O;)IB5I&"JH9T4@D="9!\/_DE\RJJGW+_,&WY%L[JJ M26"NQ/PDZ'W)DJ#9)C1R\-/WKVG02T6?[1K]&GST%`]+B(YT#PN5+)[FYUY M7Y(1K7VWV\S[N`0VZ7:9?F;2W-4@'H[ZI"#1AY]'"\A\W>X#I>>Z6YBWV0D M%=HLI&6'Y"\N5H]PWJB%8@153Q'0E=I?RR^D,G6X7?WQHJ\A\,>]-G86GPNT M.T.@:+'[>QU1C:"&&"AP/8W74<<&SNR]LB.!$F@KX5J944:C2-)]I]U-^B MCGV[FI%WSE^=RTD%V2[!B:EX9LR0/DT'2#^&N>CC>O9[ER:2WW/E!WY?YDM MXPD5Q9!8UJ``D\&(KB/`!5QJ(QKICH/:+YH=Q?&>:'KK^91U?C<3L[(N3QR14Z:B9/R M-LG-2MN?M=NSO>KWMMMPRQWD=,DV[U"7KY:2)``@L:=%4?N#O_`">R[5[N M[,B6#]B[I;TEC&[0+F.A>U=A\6L&(DFA517JOO<77>XNKF+RL.VW.VW>W.\\PP-#8;HJ;7OT3+H:WO%'^)[D4(!0L0&9B`JNL@ MRQZBV[VFZV6Y78^6;A9MRVAGW?EV56#K=6+G_'MK$@)#A02J"6:-HF[5'25 MP?RFR_>O<'S$VK\4LK+2=E?S%-W_`!)VEUWFRROD^J.O8?C!19+OWL;-T]+, MLU+6=38&HFQK%'CD3-3Q>(L\>DK+CE&'E_9>2;SF^(':^68=QDF7\-Q,;\K: M0H2$7#@/D$>$#7!KTBMN=)^9=^Y^LN29RN[\US[9%`_XK:`;<&O9W`-0;9" M8\$$2E=-2=;(?3'4>R>A>J=@]-=21O4Q]XP;YO-_S%O&X[YN=%&68^;,:LY_$Q).3T)OLJZ..O>_ M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_= M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW MOW7NM?\`_G5?'S^8/\O8MC]%_&[J^AR_0F+@I-Z[WSY['V-MNMWGOM:FOIL5 MM^NQ&X=P8BO3![.HHEJX[H\-76UJN?521$9&>Q7,GMOR6;_F#FC=F3F)R8HD M\&5Q%%0%G#(C#7(>T\"JJ1P<]8O?>&Y6]T^>UVWEOE'9EDY80":9_'AC,LU6 M"H5=U;1$.X8(9W!XQCH\'\JKX;93X1_$/:76.\:+&TO:NY,QF>P.UFQE539& MGCW5G)(J2BQ$>4I"]/71[=VQC:"B9XGD@:HBE>)F1PQ`7N]SO%SYSI>[K92, M=HB18;?4"I\-,EM)R-]^Z]U[W[KW7O?NO=>]^Z]U[W M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO= M>]^Z]T"7R+W!WKM?IW>&<^->PMJ]F]ST,.-.SME[USXVUMS+239>@@RIKLJU M7CD1Z'"R5%1%$U52K/+$L9E35?V?Q>^>POC_LZDWAV5G1G,Q1[=[/ZLH,'0F&AH\70T&, MI:K?U=5)24.-Q\,2F:>:9]&IW9R2#V2ZW$=Q;@H`H509F- M`J@9))I4DGK:D^`FY?GEEME9O;_S@ZZL;AYZ4T=&Z/%4P)/)42JE-&D8)Q%]Q;7V]AOX+GD'>[J[B MG:1IEFCB(E@4",R1LP-6!!4D!15B3UFK[87GN9/MUQ:^XVP6=E+;I$D+P2* MYF`4ARZ+)(JD40@A@"6("`#JP#W'/4H=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__T=_CW[KW7O?N MO=%E^9=%T-D?BWW?C_D[EZ+;_15?L3478.>K::MK&PF/JFA@QN7Q5)C/(9 M6JW'CKY]O;2^._9&5V#O/'[8IY(MD1UYRHV[>IH^:N?;C MGWE&\;FF>V0F(/9-!;;:"H0!Y+R!9HBY!NBI\/!\72ID'6'^Y[#!)R?[X>#J81'H[7P+J/DC3[W M'3_"'`_RKVG@S57#V365F_OE\_=U9NBIDCKZKN=^P.J,1VLVX:G(+Y_C- M)3)Y&?P1(GI`"]PUY7:_M6Y]N.;E8Q@P`0[=](Z8%MX-PUOH`H/TV8TIJ). M>I$]LFYM3;KM/;FVY91(1<$S;I]89`>XW?CVR7.LM4_JJHK72H&.C[_`'W\ MX;_GE_Y:G_H=_+_`.US[CSP_93_`)2^:?\`G%8?];NI.\3WZ_Y0^4/^\3WZ_Y0^4 M/^?S_M>.^KB_M^UC]GOJ8/H;OFWZS6-&BRUZJ]NG3-JU5X4 MS7ATGO)/>_Z2Y_>%GR9]#H/B>)-?^'HIW:]4&G33CJQ3CU0IMOK_`+'W;W?T M_G_BIW-\-^J,SBOD12R]>[+Z=K_FSNOXY[J[AHZ#(U.ZZ3JMMP?&++[+P^/R MNSXZBGW=+M7/+MY<X.12&/[>1,A[K<=LL]AWNWYOV/>[R!]L/C2W(VN.]CM MB5$9N-%\LK,LE&MQ<0^-XH_2+'4#C):;7NU]S'L-UR3S!L%C<)NH\"U;=Y+ M"2Z"L9!;:]O:)%:+4MT;:;P/"/ZH4:2+=_Y?FT_Y>N&^<'R_W)\?.TML[M^0 MN[Y9JK=?6V(V_NRDP?4-)C\M1TW;^)ZUW;N#;&WL'OC;F>[7<5,U3BM44%.M M)&B)"`7ACW'O/XM'A5T``+QN[ M]P-UD7U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO= M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[ MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=> M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>] G^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?_9 ` end